{
  "data": {
    "type": "relative_risk",
    "data": [
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BORTEZOMIB",
        "predisposition": "BORTEZOMIB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 19.88,
        "risk_count": 867,
        "predisposition_and_risk": 302,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 508262,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POMALIDOMIDE",
        "predisposition": "POMALIDOMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 17.66,
        "risk_count": 867,
        "predisposition_and_risk": 22,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 41680,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.THALIDOMIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 17.52,
        "risk_count": 867,
        "predisposition_and_risk": 100,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 190897,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CARFILZOMIB",
        "predisposition": "CARFILZOMIB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 15.83,
        "risk_count": 867,
        "predisposition_and_risk": 72,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 152143,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MELPHALAN",
        "predisposition": "MELPHALAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 15.75,
        "risk_count": 867,
        "predisposition_and_risk": 25,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 53094,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LENALIDOMIDE",
        "predisposition": "LENALIDOMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 15.35,
        "risk_count": 867,
        "predisposition_and_risk": 106,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 230955,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BORTEZOMIB",
        "predisposition": "BORTEZOMIB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 13.42,
        "risk_count": 811,
        "predisposition_and_risk": 236,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 508614,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POMALIDOMIDE",
        "predisposition": "POMALIDOMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 12.64,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 25168,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LENALIDOMIDE",
        "predisposition": "LENALIDOMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 12.48,
        "risk_count": 811,
        "predisposition_and_risk": 130,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 301156,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MELPHALAN",
        "predisposition": "MELPHALAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 12.48,
        "risk_count": 811,
        "predisposition_and_risk": 35,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 81078,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THALIDOMIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 10.67,
        "risk_count": 811,
        "predisposition_and_risk": 94,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 254815,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CARFILZOMIB",
        "predisposition": "CARFILZOMIB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 9.09,
        "risk_count": 811,
        "predisposition_and_risk": 60,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 190951,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PAMIDRONIC_ACID",
        "predisposition": "PAMIDRONIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 9.01,
        "risk_count": 811,
        "predisposition_and_risk": 257,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 825029,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PAMIDRONIC_ACID",
        "predisposition": "PAMIDRONIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 7.52,
        "risk_count": 867,
        "predisposition_and_risk": 319,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1419393,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DAPSONE",
        "predisposition": "DAPSONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 6.06,
        "risk_count": 867,
        "predisposition_and_risk": 12,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 66284,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLODRONIC_ACID",
        "predisposition": "CLODRONIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 5.56,
        "risk_count": 811,
        "predisposition_and_risk": 36,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 187322,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BENDAMUSTINE",
        "predisposition": "BENDAMUSTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 3.29,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 105575,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SIMILAC_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.78,
        "risk_count": 811,
        "predisposition_and_risk": 15,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 155818,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CYCLOPHOSPHAMIDE",
        "predisposition": "CYCLOPHOSPHAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.77,
        "risk_count": 811,
        "predisposition_and_risk": 22,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 230081,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FILGRASTIM",
        "predisposition": "FILGRASTIM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.64,
        "risk_count": 811,
        "predisposition_and_risk": 59,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 645636,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LAMIVUDINE",
        "predisposition": "LAMIVUDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.59,
        "risk_count": 867,
        "predisposition_and_risk": 86,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1110440,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IMMUNOGLOBULINS_IV_HUMAN",
        "predisposition": "IMMUNOGLOBULINS IV HUMAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.52,
        "risk_count": 867,
        "predisposition_and_risk": 88,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1169319,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CYCLOPHOSPHAMIDE",
        "predisposition": "CYCLOPHOSPHAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.36,
        "risk_count": 867,
        "predisposition_and_risk": 26,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 368549,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ERLOTINIB",
        "predisposition": "ERLOTINIB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.22,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 156600,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GRANISETRON",
        "predisposition": "GRANISETRON",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.21,
        "risk_count": 867,
        "predisposition_and_risk": 62,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 937898,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALCIUM_FOLINATE",
        "predisposition": "CALCIUM FOLINATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.19,
        "risk_count": 867,
        "predisposition_and_risk": 21,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 321100,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CO.2DTRIMOXAZOLE_CD",
        "predisposition": "CO-TRIMOXAZOLE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.15,
        "risk_count": 811,
        "predisposition_and_risk": 267,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3592643,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACICLOVIR",
        "predisposition": "ACICLOVIR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.14,
        "risk_count": 811,
        "predisposition_and_risk": 291,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3926962,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BP_MONITOR",
        "predisposition": "BP MONITOR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.14,
        "risk_count": 867,
        "predisposition_and_risk": 14,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 218607,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CO.2DTRIMOXAZOLE_CD",
        "predisposition": "CO-TRIMOXAZOLE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.14,
        "risk_count": 867,
        "predisposition_and_risk": 236,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3694933,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PERICIAZINE",
        "predisposition": "PERICIAZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.14,
        "risk_count": 867,
        "predisposition_and_risk": 18,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 281108,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IMMUNOGLOBULINS_IV_HUMAN",
        "predisposition": "IMMUNOGLOBULINS IV HUMAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.13,
        "risk_count": 811,
        "predisposition_and_risk": 74,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1005772,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENSURE_CD",
        "predisposition": "ENSURE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.08,
        "risk_count": 867,
        "predisposition_and_risk": 14,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 224655,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PEGFILGRASTIM",
        "predisposition": "PEGFILGRASTIM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.05,
        "risk_count": 811,
        "predisposition_and_risk": 41,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 579651,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHAMOMILE",
        "predisposition": "CHAMOMILE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.04,
        "risk_count": 811,
        "predisposition_and_risk": 14,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 198251,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALCIUM_FOLINATE",
        "predisposition": "CALCIUM FOLINATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 2.02,
        "risk_count": 811,
        "predisposition_and_risk": 13,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 186082,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLODRONIC_ACID",
        "predisposition": "CLODRONIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.98,
        "risk_count": 867,
        "predisposition_and_risk": 49,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 829488,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INFUSION_SET",
        "predisposition": "INFUSION SET",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.95,
        "risk_count": 811,
        "predisposition_and_risk": 21,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 311956,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FILGRASTIM",
        "predisposition": "FILGRASTIM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.91,
        "risk_count": 867,
        "predisposition_and_risk": 54,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 944053,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ZOLEDRONIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.9,
        "risk_count": 811,
        "predisposition_and_risk": 27,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 411647,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MEDROXYPROGESTERONE",
        "predisposition": "MEDROXYPROGESTERONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.89,
        "risk_count": 867,
        "predisposition_and_risk": 11,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 194514,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ABDOMINAL_BINDER",
        "predisposition": "ABDOMINAL BINDER",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.83,
        "risk_count": 811,
        "predisposition_and_risk": 24,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 379676,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ACICLOVIR",
        "predisposition": "ACICLOVIR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.83,
        "risk_count": 867,
        "predisposition_and_risk": 362,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6612313,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LIOTHYRONINE_SODIUM",
        "predisposition": "LIOTHYRONINE SODIUM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.83,
        "risk_count": 867,
        "predisposition_and_risk": 11,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 200828,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TETRABENAZINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.8,
        "risk_count": 867,
        "predisposition_and_risk": 18,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 334689,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EVEROLIMUS",
        "predisposition": "EVEROLIMUS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.77,
        "risk_count": 867,
        "predisposition_and_risk": 26,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 491234,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GOSERELIN",
        "predisposition": "GOSERELIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.77,
        "risk_count": 811,
        "predisposition_and_risk": 30,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 490372,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXYCODONE.2C_AND_NALOXONE",
        "predisposition": "OXYCODONE, AND NALOXONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.76,
        "risk_count": 811,
        "predisposition_and_risk": 181,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2969987,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CYCLOPENTOLATE",
        "predisposition": "CYCLOPENTOLATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.73,
        "risk_count": 867,
        "predisposition_and_risk": 13,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 251748,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.JEVITY_LIQ.2E_CD",
        "predisposition": "JEVITY LIQ. CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.73,
        "risk_count": 867,
        "predisposition_and_risk": 38,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 733203,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DISOPYRAMIDE",
        "predisposition": "DISOPYRAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.72,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 201711,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GAVISCON_ADVANCE_CD",
        "predisposition": "GAVISCON ADVANCE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.72,
        "risk_count": 811,
        "predisposition_and_risk": 24,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 403090,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DESIPRAMINE",
        "predisposition": "DESIPRAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.71,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 202340,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.X5.2E00CM",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.71,
        "risk_count": 867,
        "predisposition_and_risk": 12,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 235037,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PRAMIPEXOLE",
        "predisposition": "PRAMIPEXOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.7,
        "risk_count": 867,
        "predisposition_and_risk": 30,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 591606,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VIBROCIL_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.7,
        "risk_count": 867,
        "predisposition_and_risk": 13,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 256508,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENTACAPONE",
        "predisposition": "ENTACAPONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.66,
        "risk_count": 811,
        "predisposition_and_risk": 29,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 505509,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ONDANSETRON",
        "predisposition": "ONDANSETRON",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.66,
        "risk_count": 811,
        "predisposition_and_risk": 33,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 573175,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.X5.2E0ML",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.66,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 191504,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYIGENE_PADS",
        "predisposition": "HYIGENE PADS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.64,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 211643,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KETOPROFEN",
        "predisposition": "KETOPROFEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.64,
        "risk_count": 867,
        "predisposition_and_risk": 29,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 591236,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYCODONE.2C_AND_NALOXONE",
        "predisposition": "OXYCODONE, AND NALOXONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.64,
        "risk_count": 867,
        "predisposition_and_risk": 151,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3076363,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NEPHROCARE_CD",
        "predisposition": "NEPHROCARE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.63,
        "risk_count": 867,
        "predisposition_and_risk": 37,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 759645,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VIBROCIL_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.63,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 195009,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SAXAGLIPTIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.62,
        "risk_count": 811,
        "predisposition_and_risk": 33,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 589171,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENTECAVIR",
        "predisposition": "ENTECAVIR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.61,
        "risk_count": 867,
        "predisposition_and_risk": 21,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 436512,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FENTANYL",
        "predisposition": "FENTANYL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.61,
        "risk_count": 811,
        "predisposition_and_risk": 240,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4322276,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ZOLMITRIPTAN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.6,
        "risk_count": 867,
        "predisposition_and_risk": 29,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 608111,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CRANBERRY_CONC.2ECD",
        "predisposition": "CRANBERRY CONC.CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.59,
        "risk_count": 811,
        "predisposition_and_risk": 30,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 546419,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL.2DBIMATOPROST_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.59,
        "risk_count": 867,
        "predisposition_and_risk": 19,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 399815,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EPINEPHRINE",
        "predisposition": "EPINEPHRINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.58,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 201480,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MORPHINE",
        "predisposition": "MORPHINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.58,
        "risk_count": 811,
        "predisposition_and_risk": 79,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1449703,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXAMETHASONE",
        "predisposition": "DEXAMETHASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.57,
        "risk_count": 867,
        "predisposition_and_risk": 361,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7694218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FENTANYL",
        "predisposition": "FENTANYL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.57,
        "risk_count": 867,
        "predisposition_and_risk": 243,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5177961,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FORMOTEROL_AND_BECLOMETASONE",
        "predisposition": "FORMOTEROL AND BECLOMETASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.57,
        "risk_count": 811,
        "predisposition_and_risk": 20,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 369473,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROGYLUTON_CD",
        "predisposition": "PROGYLUTON CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.57,
        "risk_count": 867,
        "predisposition_and_risk": 13,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 277025,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NECK_BRACE",
        "predisposition": "NECK BRACE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.56,
        "risk_count": 867,
        "predisposition_and_risk": 22,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 471389,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SOD_CHLORIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.56,
        "risk_count": 867,
        "predisposition_and_risk": 12,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 257565,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL.2DTRAVOPROST_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.56,
        "risk_count": 867,
        "predisposition_and_risk": 31,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 665919,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RITUXIMAB",
        "predisposition": "RITUXIMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.55,
        "risk_count": 811,
        "predisposition_and_risk": 36,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 670346,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TENOFOVIR_DISOPROXIL_AND_EMTRICITABINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.55,
        "risk_count": 867,
        "predisposition_and_risk": 11,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 237088,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MEGESTROL",
        "predisposition": "MEGESTROL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.54,
        "risk_count": 867,
        "predisposition_and_risk": 24,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 522463,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BEVACIZUMAB",
        "predisposition": "BEVACIZUMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.53,
        "risk_count": 811,
        "predisposition_and_risk": 25,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 472971,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CYCLOPENTOLATE",
        "predisposition": "CYCLOPENTOLATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.53,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 207566,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LAMIVUDINE",
        "predisposition": "LAMIVUDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.53,
        "risk_count": 811,
        "predisposition_and_risk": 97,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1831005,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ONDANSETRON",
        "predisposition": "ONDANSETRON",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.53,
        "risk_count": 867,
        "predisposition_and_risk": 45,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 984389,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TENOFOVIR_DISOPROXIL_AND_EMTRICITABINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.53,
        "risk_count": 811,
        "predisposition_and_risk": 16,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 303158,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRASTUZUMAB",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.53,
        "risk_count": 867,
        "predisposition_and_risk": 74,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1619379,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GUAIFENESIN",
        "predisposition": "GUAIFENESIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.52,
        "risk_count": 867,
        "predisposition_and_risk": 19,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 419318,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ISOCONAZOLE",
        "predisposition": "ISOCONAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.52,
        "risk_count": 811,
        "predisposition_and_risk": 24,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 455593,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NORTRIPTYLINE",
        "predisposition": "NORTRIPTYLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.52,
        "risk_count": 867,
        "predisposition_and_risk": 39,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 857129,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BETANECHOL",
        "predisposition": "BETANECHOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.51,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 210303,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.KETOTIFEN",
        "predisposition": "KETOTIFEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.51,
        "risk_count": 811,
        "predisposition_and_risk": 20,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 383250,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NICOTINIC_ACID.2DLAROPIPRANT_CD",
        "predisposition": "NICOTINIC ACID-LAROPIPRANT CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.49,
        "risk_count": 811,
        "predisposition_and_risk": 16,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 309718,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TAMOXIFEN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.49,
        "risk_count": 811,
        "predisposition_and_risk": 16,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 311555,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NORETHISTERONE",
        "predisposition": "NORETHISTERONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.48,
        "risk_count": 867,
        "predisposition_and_risk": 15,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 339283,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALCIUM.2DMAGNESIUM.2BZINC_CD",
        "predisposition": "CALCIUM-MAGNESIUM+ZINC CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.47,
        "risk_count": 811,
        "predisposition_and_risk": 29,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 570199,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DEXAMETHASONE",
        "predisposition": "DEXAMETHASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.47,
        "risk_count": 811,
        "predisposition_and_risk": 303,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5955382,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.X5.2E0ML",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.47,
        "risk_count": 867,
        "predisposition_and_risk": 12,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 272678,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OPTRYL_CD",
        "predisposition": "OPTRYL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.46,
        "risk_count": 867,
        "predisposition_and_risk": 63,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1438876,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TROMANTADINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.46,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 238029,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VILDAGLIPTIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.46,
        "risk_count": 867,
        "predisposition_and_risk": 73,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1667591,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALPHOSYL_.22.222_IN_1.22.22_CD",
        "predisposition": "ALPHOSYL \"\"2 IN 1\"\" CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.45,
        "risk_count": 867,
        "predisposition_and_risk": 47,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1088013,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BECLOMETHASONE",
        "predisposition": "BECLOMETHASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.45,
        "risk_count": 867,
        "predisposition_and_risk": 33,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 760471,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BENZATHINE_BENZYLPENICILLIN.2DLIDOCANIN_CD",
        "predisposition": "BENZATHINE BENZYLPENICILLIN-LIDOCANIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.45,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 239222,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PEMETREXED",
        "predisposition": "PEMETREXED",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.45,
        "risk_count": 811,
        "predisposition_and_risk": 13,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 259999,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.STALEVO_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.45,
        "risk_count": 811,
        "predisposition_and_risk": 50,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 998595,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LABETALOL",
        "predisposition": "LABETALOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.44,
        "risk_count": 811,
        "predisposition_and_risk": 14,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 281098,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RIVASTIGMINE",
        "predisposition": "RIVASTIGMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.44,
        "risk_count": 811,
        "predisposition_and_risk": 39,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 784055,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MODAFINIL",
        "predisposition": "MODAFINIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.43,
        "risk_count": 867,
        "predisposition_and_risk": 14,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 326901,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FORMOTEROL_AND_BECLOMETASONE",
        "predisposition": "FORMOTEROL AND BECLOMETASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.42,
        "risk_count": 867,
        "predisposition_and_risk": 21,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 493608,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LINAGLIPTIN_AND_EMPAGLIFLOZIN",
        "predisposition": "LINAGLIPTIN AND EMPAGLIFLOZIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.42,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 223931,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ERYTHROPOIETIN",
        "predisposition": "ERYTHROPOIETIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.41,
        "risk_count": 867,
        "predisposition_and_risk": 336,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7948042,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GEMCITABINE",
        "predisposition": "GEMCITABINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.41,
        "risk_count": 811,
        "predisposition_and_risk": 32,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 656217,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL.2DTRAVOPROST_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.41,
        "risk_count": 811,
        "predisposition_and_risk": 29,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 593161,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ZOLEDRONIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.41,
        "risk_count": 867,
        "predisposition_and_risk": 50,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1182414,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CROMOGLICIC_ACID",
        "predisposition": "CROMOGLICIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.4,
        "risk_count": 867,
        "predisposition_and_risk": 59,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1408181,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DAKTACORT_CD",
        "predisposition": "DAKTACORT CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.4,
        "risk_count": 811,
        "predisposition_and_risk": 56,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1157846,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHENAMINE",
        "predisposition": "METHENAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.4,
        "risk_count": 811,
        "predisposition_and_risk": 29,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 599091,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TEEJEL_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.4,
        "risk_count": 811,
        "predisposition_and_risk": 17,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 352380,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VINORELBINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.4,
        "risk_count": 867,
        "predisposition_and_risk": 28,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 668647,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACETAZOLAMIDE",
        "predisposition": "ACETAZOLAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.39,
        "risk_count": 811,
        "predisposition_and_risk": 81,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1688879,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DELMOPINOL",
        "predisposition": "DELMOPINOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.39,
        "risk_count": 867,
        "predisposition_and_risk": 17,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 409722,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DESMOPRESSIN",
        "predisposition": "DESMOPRESSIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.39,
        "risk_count": 867,
        "predisposition_and_risk": 36,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 868585,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DRONEDARONE",
        "predisposition": "DRONEDARONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.39,
        "risk_count": 867,
        "predisposition_and_risk": 28,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 675318,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAGNESIUM_SULFATE",
        "predisposition": "MAGNESIUM SULFATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.39,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 248817,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACENOCOUMAROL",
        "predisposition": "ACENOCOUMAROL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.38,
        "risk_count": 811,
        "predisposition_and_risk": 61,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1281042,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHLORHEXIDINE_COMBINATIONS_CD",
        "predisposition": "CHLORHEXIDINE COMBINATIONS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.38,
        "risk_count": 811,
        "predisposition_and_risk": 78,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1634304,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EUCALYPTUS_OIL",
        "predisposition": "EUCALYPTUS OIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.38,
        "risk_count": 811,
        "predisposition_and_risk": 22,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 460696,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SILVER_SULFADIAZINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.38,
        "risk_count": 811,
        "predisposition_and_risk": 115,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2406557,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLUCERNA_CD",
        "predisposition": "GLUCERNA CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.37,
        "risk_count": 811,
        "predisposition_and_risk": 37,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 778384,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IBUPROPHEN_.2D_PSEUDOEPHEDRINE_CD",
        "predisposition": "IBUPROPHEN - PSEUDOEPHEDRINE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.37,
        "risk_count": 811,
        "predisposition_and_risk": 28,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 589791,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PILOCARPINE",
        "predisposition": "PILOCARPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.37,
        "risk_count": 867,
        "predisposition_and_risk": 51,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1241227,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POLYETHYLENE_GLYCOL_400.2DPROPYLENE_GLYCOL_CD",
        "predisposition": "POLYETHYLENE GLYCOL 400-PROPYLENE GLYCOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.37,
        "risk_count": 867,
        "predisposition_and_risk": 21,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 511153,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IMATINIB",
        "predisposition": "IMATINIB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.36,
        "risk_count": 811,
        "predisposition_and_risk": 34,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 725023,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MEMANTINE",
        "predisposition": "MEMANTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.36,
        "risk_count": 811,
        "predisposition_and_risk": 27,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 574262,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MULTIDERM_CD",
        "predisposition": "MULTIDERM CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.36,
        "risk_count": 867,
        "predisposition_and_risk": 17,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 417115,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NEPHROCARE_CD",
        "predisposition": "NEPHROCARE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.36,
        "risk_count": 811,
        "predisposition_and_risk": 40,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 849693,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PYRIDOSTIGMINE",
        "predisposition": "PYRIDOSTIGMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.36,
        "risk_count": 867,
        "predisposition_and_risk": 34,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 837669,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BICALUTAMIDE",
        "predisposition": "BICALUTAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.35,
        "risk_count": 811,
        "predisposition_and_risk": 38,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 814628,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BUPRENORPHINE",
        "predisposition": "BUPRENORPHINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.35,
        "risk_count": 811,
        "predisposition_and_risk": 53,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1134249,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLUVOXAMINE",
        "predisposition": "FLUVOXAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.35,
        "risk_count": 811,
        "predisposition_and_risk": 103,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2211577,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.KERATOSPOR_CD",
        "predisposition": "KERATOSPOR CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.35,
        "risk_count": 811,
        "predisposition_and_risk": 28,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 601946,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PHENYPHRINE.2DAZOL_CD",
        "predisposition": "PHENYPHRINE-AZOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.34,
        "risk_count": 811,
        "predisposition_and_risk": 15,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 323554,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AEROCHAMBER",
        "predisposition": "AEROCHAMBER",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.33,
        "risk_count": 811,
        "predisposition_and_risk": 17,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 369789,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DESIPRAMINE",
        "predisposition": "DESIPRAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.33,
        "risk_count": 867,
        "predisposition_and_risk": 16,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 403186,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.KETOPROFEN",
        "predisposition": "KETOPROFEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.33,
        "risk_count": 811,
        "predisposition_and_risk": 15,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 325904,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METHYLDOPA_.28RACEMIC.29",
        "predisposition": "METHYLDOPA (RACEMIC)",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.33,
        "risk_count": 867,
        "predisposition_and_risk": 19,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 477484,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYCODONE",
        "predisposition": "OXYCODONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.33,
        "risk_count": 867,
        "predisposition_and_risk": 343,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8646059,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PENFLURIDOL",
        "predisposition": "PENFLURIDOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.33,
        "risk_count": 811,
        "predisposition_and_risk": 18,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 391991,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PRASUGREL",
        "predisposition": "PRASUGREL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.33,
        "risk_count": 867,
        "predisposition_and_risk": 30,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 755290,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.URINE_BAG",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.33,
        "risk_count": 867,
        "predisposition_and_risk": 71,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1783383,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FERRIC_HYDROXIDE_POLYMALTOSE_COMPLEX",
        "predisposition": "FERRIC HYDROXIDE POLYMALTOSE COMPLEX",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.32,
        "risk_count": 867,
        "predisposition_and_risk": 21,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 531148,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUOROURACIL",
        "predisposition": "FLUOROURACIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.32,
        "risk_count": 867,
        "predisposition_and_risk": 37,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 938074,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INTERFERON_BETA.2D1A",
        "predisposition": "INTERFERON BETA-1A",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.32,
        "risk_count": 811,
        "predisposition_and_risk": 13,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 284790,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NECK_BRACE",
        "predisposition": "NECK BRACE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.32,
        "risk_count": 811,
        "predisposition_and_risk": 13,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 283761,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CROTAMITON",
        "predisposition": "CROTAMITON",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.31,
        "risk_count": 867,
        "predisposition_and_risk": 66,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1682902,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLOVE",
        "predisposition": "GLOVE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.31,
        "risk_count": 811,
        "predisposition_and_risk": 52,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1148084,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYPERICI_HERBA",
        "predisposition": "HYPERICI HERBA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.31,
        "risk_count": 811,
        "predisposition_and_risk": 41,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 903750,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IMIPRAMINE",
        "predisposition": "IMIPRAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.31,
        "risk_count": 867,
        "predisposition_and_risk": 50,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1278325,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAALOX_PLUS_CD",
        "predisposition": "MAALOX PLUS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.31,
        "risk_count": 867,
        "predisposition_and_risk": 63,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1610831,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TAROCIDIN.2FPHENIMIXIN_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.31,
        "risk_count": 867,
        "predisposition_and_risk": 143,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3641216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TOLTERODINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.31,
        "risk_count": 867,
        "predisposition_and_risk": 208,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5328528,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ANTITHYROID_PREPERATIONS",
        "predisposition": "ANTITHYROID PREPERATIONS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 811,
        "predisposition_and_risk": 38,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 845628,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BUSERELIN",
        "predisposition": "BUSERELIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 811,
        "predisposition_and_risk": 13,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 288749,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOXYLAMINE",
        "predisposition": "DOXYLAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 867,
        "predisposition_and_risk": 30,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 769160,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EPINASTIN_HCL",
        "predisposition": "EPINASTIN HCL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 867,
        "predisposition_and_risk": 11,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 283054,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDROAGISTEN_CD",
        "predisposition": "HYDROAGISTEN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 811,
        "predisposition_and_risk": 92,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2051679,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PHENOBARBITAL",
        "predisposition": "PHENOBARBITAL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 867,
        "predisposition_and_risk": 90,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2324214,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROPAFENONE",
        "predisposition": "PROPAFENONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 867,
        "predisposition_and_risk": 246,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6324966,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SELEGILINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 867,
        "predisposition_and_risk": 28,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 718619,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TENOFOVIR_DISOPROXIL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 811,
        "predisposition_and_risk": 29,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 645489,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL.2DBRIMONIDINE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.3,
        "risk_count": 811,
        "predisposition_and_risk": 41,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 909776,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AMISULPRIDE",
        "predisposition": "AMISULPRIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.29,
        "risk_count": 867,
        "predisposition_and_risk": 32,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 828411,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ARIPIPRAZOLE",
        "predisposition": "ARIPIPRAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.29,
        "risk_count": 867,
        "predisposition_and_risk": 24,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 623749,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AZATHIOPRINE",
        "predisposition": "AZATHIOPRINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.29,
        "risk_count": 867,
        "predisposition_and_risk": 105,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2732887,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLUCOSE",
        "predisposition": "GLUCOSE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.29,
        "risk_count": 811,
        "predisposition_and_risk": 17,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 382544,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GRANISETRON",
        "predisposition": "GRANISETRON",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.29,
        "risk_count": 811,
        "predisposition_and_risk": 26,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 582113,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METFORMIN_AND_DAPAGLIFLOZIN",
        "predisposition": "METFORMIN AND DAPAGLIFLOZIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.29,
        "risk_count": 867,
        "predisposition_and_risk": 11,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 284799,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PENCICLOVIR",
        "predisposition": "PENCICLOVIR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.29,
        "risk_count": 867,
        "predisposition_and_risk": 41,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1059962,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POVIDONE_COMP_CD",
        "predisposition": "POVIDONE COMP CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.29,
        "risk_count": 811,
        "predisposition_and_risk": 44,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 987889,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THYME_LIQUID_EXTRACT",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.29,
        "risk_count": 811,
        "predisposition_and_risk": 27,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 606953,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.COD.2DGUAIACOL_CD",
        "predisposition": "COD-GUAIACOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.28,
        "risk_count": 811,
        "predisposition_and_risk": 68,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1533171,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DESMOPRESSIN",
        "predisposition": "DESMOPRESSIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.28,
        "risk_count": 811,
        "predisposition_and_risk": 34,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 767703,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FORMOTEROL_AND_FLUTICASONE",
        "predisposition": "FORMOTEROL AND FLUTICASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.28,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 271783,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ICHYTHOL_.2D_ZINC_OXIDE_.2D_TITANIUM_OXIDE_COMP.2E_CD",
        "predisposition": "ICHYTHOL - ZINC OXIDE - TITANIUM OXIDE COMP. CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.28,
        "risk_count": 867,
        "predisposition_and_risk": 19,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 496063,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROBIOTIC",
        "predisposition": "PROBIOTIC",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.28,
        "risk_count": 867,
        "predisposition_and_risk": 84,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2202023,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SALMETEROL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.28,
        "risk_count": 811,
        "predisposition_and_risk": 54,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1221820,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VALGANCICLOVIR",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.28,
        "risk_count": 811,
        "predisposition_and_risk": 22,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 496169,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALCIPOTRIOL",
        "predisposition": "CALCIPOTRIOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.27,
        "risk_count": 867,
        "predisposition_and_risk": 20,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 525124,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EYE_CARE_WIPES",
        "predisposition": "EYE CARE WIPES",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.27,
        "risk_count": 811,
        "predisposition_and_risk": 29,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 659769,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POTASSIUM_CHLORIDE",
        "predisposition": "POTASSIUM CHLORIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.27,
        "risk_count": 811,
        "predisposition_and_risk": 205,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4654749,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROBIOTIC",
        "predisposition": "PROBIOTIC",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.27,
        "risk_count": 811,
        "predisposition_and_risk": 27,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 614481,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RISEDRONIC_ACID",
        "predisposition": "RISEDRONIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.27,
        "risk_count": 811,
        "predisposition_and_risk": 130,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2949968,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SILVER_DRESSING",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.27,
        "risk_count": 867,
        "predisposition_and_risk": 21,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 551611,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL.2D_BRINZOLAMIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.27,
        "risk_count": 867,
        "predisposition_and_risk": 29,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 764725,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CAST",
        "predisposition": "CAST",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 83,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1903333,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ISOCONAZOLE",
        "predisposition": "ISOCONAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 867,
        "predisposition_and_risk": 19,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 503793,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LAXATIVE_COMP.2E_CD",
        "predisposition": "LAXATIVE COMP. CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 34,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 781582,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MEROKEN_NEW_CD",
        "predisposition": "MEROKEN NEW CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 118,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2716878,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METHYLPREDNISOLONE_.2D_LIDOCAINE_CD",
        "predisposition": "METHYLPREDNISOLONE - LIDOCAINE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 867,
        "predisposition_and_risk": 27,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 718380,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NORTRIPTYLINE",
        "predisposition": "NORTRIPTYLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 23,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 529229,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXCARBAZEPINE",
        "predisposition": "OXCARBAZEPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 27,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 619652,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXCARBAZEPINE",
        "predisposition": "OXCARBAZEPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 867,
        "predisposition_and_risk": 17,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 451496,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PRIMIDONE",
        "predisposition": "PRIMIDONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 867,
        "predisposition_and_risk": 36,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 953642,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RADIAN_B_CD",
        "predisposition": "RADIAN B CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 867,
        "predisposition_and_risk": 51,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1353483,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RENNIE_CD",
        "predisposition": "RENNIE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 49,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1126776,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ROPINIROLE",
        "predisposition": "ROPINIROLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 57,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1311346,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.STOMA",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 867,
        "predisposition_and_risk": 128,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3401051,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SULFASALAZINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 42,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 967484,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TAMSULOSIN_AND_DUTASTERIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 217,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4961382,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VILANTEROL_AND_FLUTICASONE_FUROATE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 122,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2806379,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VILANTEROL_AND_UMECLIDINIUM_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.26,
        "risk_count": 811,
        "predisposition_and_risk": 24,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 550572,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ASCORBIC_ACID.2DPROPOLIS_CD",
        "predisposition": "ASCORBIC ACID-PROPOLIS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 18,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 415861,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BETAXOLOL",
        "predisposition": "BETAXOLOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 867,
        "predisposition_and_risk": 26,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 698014,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALMANERVIN.2FPASSIFLORA_COMP.2E_CD",
        "predisposition": "CALMANERVIN/PASSIFLORA COMP. CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 107,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2478256,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CAPECITABINE",
        "predisposition": "CAPECITABINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 867,
        "predisposition_and_risk": 34,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 909019,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DAPAGLIFLOZIN",
        "predisposition": "DAPAGLIFLOZIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 127,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2947009,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DARBEPOETIN_ALFA",
        "predisposition": "DARBEPOETIN ALFA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 287,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6651195,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENOXAPARIN",
        "predisposition": "ENOXAPARIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 314,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 7292108,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ERYTHROMYCIN",
        "predisposition": "ERYTHROMYCIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 867,
        "predisposition_and_risk": 37,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 987742,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EVEROLIMUS",
        "predisposition": "EVEROLIMUS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 46,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1067105,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLOVE",
        "predisposition": "GLOVE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 867,
        "predisposition_and_risk": 66,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1759607,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLYCERYL_TRINITRATE",
        "predisposition": "GLYCERYL TRINITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 867,
        "predisposition_and_risk": 36,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 965053,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MORPHINE",
        "predisposition": "MORPHINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 867,
        "predisposition_and_risk": 54,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1447335,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POLYSTYRENE_SULFONATE",
        "predisposition": "POLYSTYRENE SULFONATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 162,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3755999,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THIORIDAZINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 58,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1344746,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL.2D_BRINZOLAMIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 25,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 580437,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.URGENIN_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.25,
        "risk_count": 811,
        "predisposition_and_risk": 55,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1274505,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACIDOPHILUS_PROBIOTIC_CD",
        "predisposition": "ACIDOPHILUS PROBIOTIC CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.24,
        "risk_count": 811,
        "predisposition_and_risk": 94,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2193426,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALCIUM.2DZINC_CD",
        "predisposition": "CALCIUM-ZINC CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.24,
        "risk_count": 867,
        "predisposition_and_risk": 11,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 296879,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DARBEPOETIN_ALFA",
        "predisposition": "DARBEPOETIN ALFA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.24,
        "risk_count": 867,
        "predisposition_and_risk": 218,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5883212,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ICHTHAMOL",
        "predisposition": "ICHTHAMOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.24,
        "risk_count": 811,
        "predisposition_and_risk": 61,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1424851,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KERATOSPOR_CD",
        "predisposition": "KERATOSPOR CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.24,
        "risk_count": 867,
        "predisposition_and_risk": 39,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1055355,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POVIDONE",
        "predisposition": "POVIDONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.24,
        "risk_count": 811,
        "predisposition_and_risk": 15,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 348811,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RECTOZORIN_CD",
        "predisposition": "RECTOZORIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.24,
        "risk_count": 867,
        "predisposition_and_risk": 62,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1668869,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TERBUTALINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.24,
        "risk_count": 867,
        "predisposition_and_risk": 124,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3357401,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VITAMIN_B_COMPLEX.2BVIT.2EC_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.24,
        "risk_count": 867,
        "predisposition_and_risk": 31,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 837656,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ANKLE_BRACE",
        "predisposition": "ANKLE BRACE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 867,
        "predisposition_and_risk": 66,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1800433,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CABERGOLINE",
        "predisposition": "CABERGOLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 811,
        "predisposition_and_risk": 41,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 962266,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CANDESARTAN_.2D_HYDROCHLOROTHIAZIDE_CD",
        "predisposition": "CANDESARTAN - HYDROCHLOROTHIAZIDE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 867,
        "predisposition_and_risk": 157,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4278561,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CICLODERM.2DC_CD",
        "predisposition": "CICLODERM-C CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 811,
        "predisposition_and_risk": 31,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 730395,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIMETHINDENE",
        "predisposition": "DIMETHINDENE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 811,
        "predisposition_and_risk": 29,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 679295,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DRONEDARONE",
        "predisposition": "DRONEDARONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 811,
        "predisposition_and_risk": 31,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 728099,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EXENATIDE",
        "predisposition": "EXENATIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 811,
        "predisposition_and_risk": 82,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1929793,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLUOROMETHOLONE",
        "predisposition": "FLUOROMETHOLONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 811,
        "predisposition_and_risk": 53,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1248546,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDRALAZINE",
        "predisposition": "HYDRALAZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 867,
        "predisposition_and_risk": 45,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1221924,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LIQUID_PARAFFIN",
        "predisposition": "LIQUID PARAFFIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 811,
        "predisposition_and_risk": 111,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2609655,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PNEUMOCOCCUS.2C_PURIFIED_POLYSACHARIDES_ANTIGEN_CONJUGATED",
        "predisposition": "PNEUMOCOCCUS, PURIFIED POLYSACHARIDES ANTIGEN CONJUGATED",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 811,
        "predisposition_and_risk": 46,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1083407,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POLYACRYLIC_ACID",
        "predisposition": "POLYACRYLIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 867,
        "predisposition_and_risk": 150,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4090073,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PYRIDOXINE_.28VITAMIN_B6.29",
        "predisposition": "PYRIDOXINE (VITAMIN B6)",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 867,
        "predisposition_and_risk": 11,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 298838,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SODIUM_CHLORIDE.2C_HYPERTONIC",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 867,
        "predisposition_and_risk": 13,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 354204,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.THIAMINE_.28VIT.2E_B1.29",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.23,
        "risk_count": 867,
        "predisposition_and_risk": 20,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 543133,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ABDOMINAL_BINDER",
        "predisposition": "ABDOMINAL BINDER",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 18,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 495303,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ALENDRONIC_ACID",
        "predisposition": "ALENDRONIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 811,
        "predisposition_and_risk": 207,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4919624,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BECLOMETHASONE",
        "predisposition": "BECLOMETHASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 811,
        "predisposition_and_risk": 22,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 521003,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BENZOYL_PEROXIDE",
        "predisposition": "BENZOYL PEROXIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 12,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 327937,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CEFTRIAXONE",
        "predisposition": "CEFTRIAXONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 811,
        "predisposition_and_risk": 28,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 663364,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXEFRIN.2FDETHAPHRINE_CD",
        "predisposition": "DEXEFRIN/DETHAPHRINE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 42,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1150245,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUOCINOLONE",
        "predisposition": "FLUOCINOLONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 31,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 848136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FULVESTRANT",
        "predisposition": "FULVESTRANT",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 16,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 437800,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYMETAZOLINE",
        "predisposition": "OXYMETAZOLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 187,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5138675,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PHENOXYMETHYLPENICILLIN",
        "predisposition": "PHENOXYMETHYLPENICILLIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 811,
        "predisposition_and_risk": 122,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2891060,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PILOCARPINE",
        "predisposition": "PILOCARPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 811,
        "predisposition_and_risk": 33,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 779831,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PIOGLITAZONE",
        "predisposition": "PIOGLITAZONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 811,
        "predisposition_and_risk": 18,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 428020,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PYRIDOSTIGMINE",
        "predisposition": "PYRIDOSTIGMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 811,
        "predisposition_and_risk": 21,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 499218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.QUININE",
        "predisposition": "QUININE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 12,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 329217,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RITUXIMAB",
        "predisposition": "RITUXIMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 28,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 769673,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SOTALOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 64,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1755854,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TAROCIDIN.2FPHENIMIXIN_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 811,
        "predisposition_and_risk": 100,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2379026,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TENOFOVIR_DISOPROXIL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 12,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 328905,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.WATER_FOR_INJECTION",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 811,
        "predisposition_and_risk": 23,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 545177,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.XYLOMETAZOLINE.2DIPRATROPIUM_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.22,
        "risk_count": 867,
        "predisposition_and_risk": 27,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 738831,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASPIRIN.2DLYSINE_ACETYLSALICYLATE",
        "predisposition": "ASPIRIN-LYSINE ACETYLSALICYLATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 96,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2653891,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BRINZOLAMIDE",
        "predisposition": "BRINZOLAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 71,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1965270,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENSURE_PLUS_CD",
        "predisposition": "ENSURE PLUS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 811,
        "predisposition_and_risk": 167,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3986150,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FERRIC_OXIDE_POLYMALTOSE_COMPLEXES",
        "predisposition": "FERRIC OXIDE POLYMALTOSE COMPLEXES",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 173,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4779696,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FINGER_DRESSING",
        "predisposition": "FINGER DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 60,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1663468,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLUCERNA_CD",
        "predisposition": "GLUCERNA CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 31,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 854010,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLYCERIN.2DSORBITOL_CD",
        "predisposition": "GLYCERIN-SORBITOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 811,
        "predisposition_and_risk": 43,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1024594,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LAXATIVE_COMP.2E_CD",
        "predisposition": "LAXATIVE COMP. CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 48,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1327113,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEVOCABASTINE",
        "predisposition": "LEVOCABASTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 67,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1854417,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MULTIVITAMINS_FOR_OCULAR_USE",
        "predisposition": "MULTIVITAMINS FOR OCULAR USE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 112,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3108281,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MUSCOL_CD",
        "predisposition": "MUSCOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 811,
        "predisposition_and_risk": 202,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4825004,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OSMOLITE_CD",
        "predisposition": "OSMOLITE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 811,
        "predisposition_and_risk": 44,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1048864,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POLYSTYRENE_SULFONATE",
        "predisposition": "POLYSTYRENE SULFONATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 96,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2664113,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POLYVINYL_ALCOHOL",
        "predisposition": "POLYVINYL ALCOHOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 811,
        "predisposition_and_risk": 16,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 381538,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RASAGILINE",
        "predisposition": "RASAGILINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 811,
        "predisposition_and_risk": 66,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1581922,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RECTOZORIN_CD",
        "predisposition": "RECTOZORIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 811,
        "predisposition_and_risk": 45,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1078964,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RIVAROXABAN",
        "predisposition": "RIVAROXABAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 125,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3464832,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SILDENAFIL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 32,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 884635,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TICAGRELOR",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.21,
        "risk_count": 867,
        "predisposition_and_risk": 27,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 749047,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CICLOPIROX",
        "predisposition": "CICLOPIROX",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 811,
        "predisposition_and_risk": 128,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3094756,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DENOSUMAB",
        "predisposition": "DENOSUMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 27,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 751709,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENTECAVIR",
        "predisposition": "ENTECAVIR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 811,
        "predisposition_and_risk": 32,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 770241,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUVASTATIN",
        "predisposition": "FLUVASTATIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 15,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 417321,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FOLEX.2FFORIC.2FFOROL_CD",
        "predisposition": "FOLEX/FORIC/FOROL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 159,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4449747,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INDACATEROL_AND_GLYCOPYRRONIUM_BROMIDE",
        "predisposition": "INDACATEROL AND GLYCOPYRRONIUM BROMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 15,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 417363,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.JUNGBORN_TEA_CD",
        "predisposition": "JUNGBORN TEA CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 48,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1342766,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MEBHYDROLIN",
        "predisposition": "MEBHYDROLIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 15,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 417156,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METHENAMINE",
        "predisposition": "METHENAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 39,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1086369,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MICROLET_CD",
        "predisposition": "MICROLET CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 811,
        "predisposition_and_risk": 103,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2477011,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MULTIVITAMINS_CD",
        "predisposition": "MULTIVITAMINS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 15,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 419763,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OLANZAPINE",
        "predisposition": "OLANZAPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 165,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4595669,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POLYVINYL_ALCOHOL",
        "predisposition": "POLYVINYL ALCOHOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 33,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 918440,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TROSPIUM",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.2,
        "risk_count": 867,
        "predisposition_and_risk": 156,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4365025,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALLOPURINOL",
        "predisposition": "ALLOPURINOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 867,
        "predisposition_and_risk": 353,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9946615,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ANKLE_BRACE",
        "predisposition": "ANKLE BRACE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 45,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1094180,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.APREPITANT",
        "predisposition": "APREPITANT",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 26,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 633631,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ATROPINE",
        "predisposition": "ATROPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 24,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 582124,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AZELASTINE",
        "predisposition": "AZELASTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 67,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1624829,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALCILESS_CD",
        "predisposition": "CALCILESS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 291726,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALCIUM.2DVITAMIN_D_CD",
        "predisposition": "CALCIUM-VITAMIN D CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 445,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10781436,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CARBOSYLANE_CD",
        "predisposition": "CARBOSYLANE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 867,
        "predisposition_and_risk": 44,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1240965,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CARBOXYMETHYLCELLULOSE",
        "predisposition": "CARBOXYMETHYLCELLULOSE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 867,
        "predisposition_and_risk": 157,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4396212,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CICLOSPORIN",
        "predisposition": "CICLOSPORIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 867,
        "predisposition_and_risk": 61,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1715310,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIPROSALIC_CD",
        "predisposition": "DIPROSALIC CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 867,
        "predisposition_and_risk": 109,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3061270,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EMPAGLIFLOZIN",
        "predisposition": "EMPAGLIFLOZIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 867,
        "predisposition_and_risk": 87,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2442252,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ERYTHROPOIETIN",
        "predisposition": "ERYTHROPOIETIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 356,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8665551,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GUAIFENESIN",
        "predisposition": "GUAIFENESIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 292354,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INDOMETACIN",
        "predisposition": "INDOMETACIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 867,
        "predisposition_and_risk": 67,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1880307,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OPTRYL_CD",
        "predisposition": "OPTRYL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 42,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1019521,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PARACETAMOL.2DASPIRIN.2DCAFFEIN_CD",
        "predisposition": "PARACETAMOL-ASPIRIN-CAFFEIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 81,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1969021,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PERMETHRIN",
        "predisposition": "PERMETHRIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 867,
        "predisposition_and_risk": 33,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 926537,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PHENOBARBITAL",
        "predisposition": "PHENOBARBITAL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 86,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2086087,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SALICYLIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 61,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1483272,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SOTALOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 128,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3098624,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TESTOSTERONE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 180,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4377091,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIOCTIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 100,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2430502,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.UMECLIDINIUM",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 27,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 656445,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VILDAGLIPTIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.19,
        "risk_count": 811,
        "predisposition_and_risk": 62,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1504264,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BEN.2DGAY_CD",
        "predisposition": "BEN-GAY CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 98,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2778279,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BIMATOPROST",
        "predisposition": "BIMATOPROST",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 88,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2492657,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENOXAPARIN",
        "predisposition": "ENOXAPARIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 303,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8554856,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EXTRA_LARGE",
        "predisposition": "EXTRA LARGE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 811,
        "predisposition_and_risk": 51,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1247585,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GEMCITABINE",
        "predisposition": "GEMCITABINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 29,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 825367,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLUCAGON",
        "predisposition": "GLUCAGON",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 811,
        "predisposition_and_risk": 23,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 565933,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDROCOLL_DRESSING",
        "predisposition": "HYDROCOLL DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 811,
        "predisposition_and_risk": 75,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1839016,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LANTHANUM_CARBONATE",
        "predisposition": "LANTHANUM CARBONATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 811,
        "predisposition_and_risk": 64,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1565967,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAGNESIUM_HYDROXIDE",
        "predisposition": "MAGNESIUM HYDROXIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 64,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1813477,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAGNESIUM_OXIDE",
        "predisposition": "MAGNESIUM OXIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 811,
        "predisposition_and_risk": 91,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2238521,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAGNESIUM_SULFATE",
        "predisposition": "MAGNESIUM SULFATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 14,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 395915,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MERCAPTOPURINE",
        "predisposition": "MERCAPTOPURINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 18,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 508645,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METOCLOPRAMIDE",
        "predisposition": "METOCLOPRAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 319,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9050239,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MONTELUKAST",
        "predisposition": "MONTELUKAST",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 811,
        "predisposition_and_risk": 70,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1710891,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NICOTINE",
        "predisposition": "NICOTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 811,
        "predisposition_and_risk": 83,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2025717,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OMALIZUMAB",
        "predisposition": "OMALIZUMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 295134,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OMALIZUMAB",
        "predisposition": "OMALIZUMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 26,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 737773,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PAPAVERINE",
        "predisposition": "PAPAVERINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 182,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5169171,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PREGABALIN",
        "predisposition": "PREGABALIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 459,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 12991328,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SODIUM_BICARBONATE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 811,
        "predisposition_and_risk": 38,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 931172,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TEARS_NATURALE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 137,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3888713,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TETRACYCLINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.18,
        "risk_count": 867,
        "predisposition_and_risk": 13,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 368491,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ATORVASTATIN_AND_EZETIMIBE",
        "predisposition": "ATORVASTATIN AND EZETIMIBE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 25,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 620096,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CARBOSYLANE_CD",
        "predisposition": "CARBOSYLANE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 34,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 840484,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOCETAXEL",
        "predisposition": "DOCETAXEL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 867,
        "predisposition_and_risk": 17,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 484371,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DORZOLAMIDE",
        "predisposition": "DORZOLAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 62,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1533688,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLECAINIDE",
        "predisposition": "FLECAINIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 85,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2094397,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GABAPENTIN",
        "predisposition": "GABAPENTIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 145,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3574648,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROXYCHLOROQUINE",
        "predisposition": "HYDROXYCHLOROQUINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 867,
        "predisposition_and_risk": 163,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4661482,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDROXYPROPYLMETHYLCELLULOSE",
        "predisposition": "HYDROXYPROPYLMETHYLCELLULOSE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 241,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5940231,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULINS_SYRINGE",
        "predisposition": "INSULINS SYRINGE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 114,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2826679,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MERIDOL_CD",
        "predisposition": "MERIDOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 96,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2376848,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MILNACIPRAN",
        "predisposition": "MILNACIPRAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 23,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 570648,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXYCODONE",
        "predisposition": "OXYCODONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 359,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8907056,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROCTOZORIN_.2D_N_CD",
        "predisposition": "PROCTOZORIN - N CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 24,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 590682,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SERENOA_REPENS",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 116,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2868108,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SEVELAMER",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 867,
        "predisposition_and_risk": 91,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2597841,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SODIUM_CHLORIDE.2C_HYPERTONIC",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 297791,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRAVOPROST",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 867,
        "predisposition_and_risk": 122,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3496662,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.URSODEOXYCHOLIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.17,
        "risk_count": 811,
        "predisposition_and_risk": 73,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1807852,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.APIXABAN",
        "predisposition": "APIXABAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 102,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2942119,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BENEFIBER",
        "predisposition": "BENEFIBER",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 125,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3618649,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXPANTHENOL.2DSODIUM_HYALURONATE_CD",
        "predisposition": "DEXPANTHENOL-SODIUM HYALURONATE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 35,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1012564,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DORZOLAMIDE",
        "predisposition": "DORZOLAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 64,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1851495,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOXEPIN",
        "predisposition": "DOXEPIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 44,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1267481,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOXYCYCLINE",
        "predisposition": "DOXYCYCLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 207,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5953877,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INHALER",
        "predisposition": "INHALER",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 811,
        "predisposition_and_risk": 12,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 300335,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IRON_INJECTION_IV",
        "predisposition": "IRON INJECTION IV",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 229,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6605809,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METFORMIN_AND_EMPAGLIFLOZIN",
        "predisposition": "METFORMIN AND EMPAGLIFLOZIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 40,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1157867,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METHOTREXATE",
        "predisposition": "METHOTREXATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 174,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5003529,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NICOTINIC_ACID",
        "predisposition": "NICOTINIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 811,
        "predisposition_and_risk": 14,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 349778,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NIFEDIPINE.2DLIDOCAINE",
        "predisposition": "NIFEDIPINE-LIDOCAINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 811,
        "predisposition_and_risk": 22,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 546531,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PREDNISONE",
        "predisposition": "PREDNISONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 613,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 17733908,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SITAGLIPTIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 296,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8527011,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.T2D.DPP_4i",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 359,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 10340012,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TINIDAZOLE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 13,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 375587,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRAZODONE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 91,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2628866,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VILDAGLIPTIN.2DMETFORMIN_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 252,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7241410,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.WATER_FOR_IRRIGATION",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.16,
        "risk_count": 867,
        "predisposition_and_risk": 162,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4655984,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASCORBIC_ACID_AND_CALCIUM_CD",
        "predisposition": "ASCORBIC ACID AND CALCIUM CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 42,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1217500,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BAMYXIN_CD",
        "predisposition": "BAMYXIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 811,
        "predisposition_and_risk": 16,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 401888,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALAMINE_LOTION_CD",
        "predisposition": "CALAMINE LOTION CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 37,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1076807,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DABIGATRAN_ETEXILATE",
        "predisposition": "DABIGATRAN ETEXILATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 80,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2328048,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIPYRIDAMOLE",
        "predisposition": "DIPYRIDAMOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 811,
        "predisposition_and_risk": 126,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3174089,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ELASTIC_BANDAGE",
        "predisposition": "ELASTIC BANDAGE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 95,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2763242,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GENTAMICIN",
        "predisposition": "GENTAMICIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 124,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3612935,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ISOSORBIDE_DINITRATE",
        "predisposition": "ISOSORBIDE DINITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 811,
        "predisposition_and_risk": 313,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 7883848,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METFORMIN_AND_LINAGLIPTIN_CD",
        "predisposition": "METFORMIN AND LINAGLIPTIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 811,
        "predisposition_and_risk": 50,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1254246,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MIDODRINE",
        "predisposition": "MIDODRINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 14,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 406079,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ORPHENADRINE",
        "predisposition": "ORPHENADRINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 25,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 725812,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PRASUGREL",
        "predisposition": "PRASUGREL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 811,
        "predisposition_and_risk": 88,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2214055,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SERTRALINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 811,
        "predisposition_and_risk": 108,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2722477,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SULFACETAMIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 35,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1015887,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TALC",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 29,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 842717,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.THERMOMETER",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 867,
        "predisposition_and_risk": 121,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3509892,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRAMADOL_AND_PARACETAMOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.15,
        "risk_count": 811,
        "predisposition_and_risk": 195,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4883013,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ACIDOPHILUS_PROBIOTIC_CD",
        "predisposition": "ACIDOPHILUS PROBIOTIC CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 177,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5171276,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BENZATHINE_BENZYLPENICILLIN",
        "predisposition": "BENZATHINE BENZYLPENICILLIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 70,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2049318,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BISMUTH_SUBSALICYLATE",
        "predisposition": "BISMUTH SUBSALICYLATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 134,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3392367,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BRONCHOLATE_NEW_FORMULA_CD",
        "predisposition": "BRONCHOLATE NEW FORMULA CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 57,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1441777,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALCIUM_GLUBIONATE",
        "predisposition": "CALCIUM GLUBIONATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 139,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4072028,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DABIGATRAN_ETEXILATE",
        "predisposition": "DABIGATRAN ETEXILATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 104,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2626728,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIETHYLTOLUAMIDE",
        "predisposition": "DIETHYLTOLUAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 19,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 482575,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIGOXIN",
        "predisposition": "DIGOXIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 284,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 7221181,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FELODIPINE",
        "predisposition": "FELODIPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 162,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4735028,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLEET_ENEMA_CD",
        "predisposition": "FLEET ENEMA CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 156,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4561320,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLEXITOL_HEEL",
        "predisposition": "FLEXITOL HEEL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 43,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1263105,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FUROSEMIDE",
        "predisposition": "FUROSEMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 649,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 19121392,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ICHTHAMOL",
        "predisposition": "ICHTHAMOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 77,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2251039,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IMIPRAMINE",
        "predisposition": "IMIPRAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 21,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 530644,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_GLULISINE",
        "predisposition": "INSULIN GLULISINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 366,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 9266101,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_LISPRO",
        "predisposition": "INSULIN LISPRO",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 201,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5912760,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IRON_INJECTION_IV",
        "predisposition": "IRON INJECTION IV",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 300,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 7584287,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ITRACONAZOLE",
        "predisposition": "ITRACONAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 21,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 534866,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LIDOCAINE",
        "predisposition": "LIDOCAINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 62,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1813377,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAXITROL_CD",
        "predisposition": "MAXITROL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 170,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4293526,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MELATONIN",
        "predisposition": "MELATONIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 32,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 808659,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHYLPREDNISOLONE_.2D_LIDOCAINE_CD",
        "predisposition": "METHYLPREDNISOLONE - LIDOCAINE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 15,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 379310,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NABUMETONE",
        "predisposition": "NABUMETONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 28,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 709958,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXYMETAZOLINE",
        "predisposition": "OXYMETAZOLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 167,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4237840,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PERPHENAZINE",
        "predisposition": "PERPHENAZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 189,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5563951,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.REBOXETINE",
        "predisposition": "REBOXETINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 71,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2079140,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SENNA_LEAVES",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 30,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 762592,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SOFFODEX_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 45,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1139536,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.T2D.SGLT2i",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 203,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5982435,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRAMADOL_AND_PARACETAMOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 301,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8831885,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRICLOSAN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 867,
        "predisposition_and_risk": 69,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2032264,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VIT.2EB12_COMBINATIONS_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 263,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6657305,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VITA.2DCAL.2BD.2BMINERALS_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.14,
        "risk_count": 811,
        "predisposition_and_risk": 58,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1467097,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AGIOLAX_CD",
        "predisposition": "AGIOLAX CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 89,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2280974,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ATORVASTATIN_AND_EZETIMIBE",
        "predisposition": "ATORVASTATIN AND EZETIMIBE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 22,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 650952,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BABY_PASTE_CD",
        "predisposition": "BABY PASTE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 177,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5257277,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BALNEUM_CD",
        "predisposition": "BALNEUM CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 43,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1278173,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BENZATHINE_BENZYLPENICILLIN",
        "predisposition": "BENZATHINE BENZYLPENICILLIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 67,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1712282,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BRIMONIDINE",
        "predisposition": "BRIMONIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 246,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6276510,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BRONCHOLATE_FORTE_CD",
        "predisposition": "BRONCHOLATE FORTE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 55,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1403493,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CODEINE",
        "predisposition": "CODEINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 232,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5956787,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DONEPEZIL",
        "predisposition": "DONEPEZIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 29,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 743239,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLECAINIDE",
        "predisposition": "FLECAINIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 114,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3377357,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLUOROURACIL",
        "predisposition": "FLUOROURACIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 39,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 995144,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GABAPENTIN",
        "predisposition": "GABAPENTIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 138,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4081011,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLIPIZIDE",
        "predisposition": "GLIPIZIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 305,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9000744,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLYCERYL_TRINITRATE",
        "predisposition": "GLYCERYL TRINITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 56,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1439417,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN.2C_BIPHASIC_ISOPHANE",
        "predisposition": "INSULIN, BIPHASIC ISOPHANE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 341,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 10120468,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.JUNGBORN_TEA_CD",
        "predisposition": "JUNGBORN TEA CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 23,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 590376,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LABETALOL",
        "predisposition": "LABETALOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 12,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 355522,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LACRIMOL_CD",
        "predisposition": "LACRIMOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 192,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4924230,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LOCAL_ANESTHETICS",
        "predisposition": "LOCAL ANESTHETICS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 252,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7436156,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LORNOXICAM",
        "predisposition": "LORNOXICAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 101,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2594882,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MESALAZINE",
        "predisposition": "MESALAZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 136,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3494612,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NET_DRESSING",
        "predisposition": "NET DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 55,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1411924,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ORPHENADRINE",
        "predisposition": "ORPHENADRINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 14,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 357500,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PEGFILGRASTIM",
        "predisposition": "PEGFILGRASTIM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 34,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1008796,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PHENOXYBENZAMINE",
        "predisposition": "PHENOXYBENZAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 47,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1202967,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SERTRALINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 150,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4434837,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TERPENES_COMP_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 53,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1357426,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THREOLONE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 811,
        "predisposition_and_risk": 63,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1609296,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRANEXAMIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.13,
        "risk_count": 867,
        "predisposition_and_risk": 16,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 473155,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACETYLCYSTEINE",
        "predisposition": "ACETYLCYSTEINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 382,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 9842524,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.APREPITANT",
        "predisposition": "APREPITANT",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 44,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1318567,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BRINZOLAMIDE",
        "predisposition": "BRINZOLAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 56,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1444877,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CABERGOLINE",
        "predisposition": "CABERGOLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 17,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 507913,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CATHETER_SUPP.2E",
        "predisposition": "CATHETER SUPP.",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 63,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1882396,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CIMETIDINE",
        "predisposition": "CIMETIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 21,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 628714,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLONIDINE",
        "predisposition": "CLONIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 268,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6928779,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DOXYCYCLINE",
        "predisposition": "DOXYCYCLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 174,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4493593,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EASY_IRON_CD",
        "predisposition": "EASY IRON CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 151,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4505778,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EXENATIDE",
        "predisposition": "EXENATIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 101,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3005824,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FERRIFOL_CD",
        "predisposition": "FERRIFOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 89,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2288346,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FERROUS_CALCIUM_CITRATE",
        "predisposition": "FERROUS CALCIUM CITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 66,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1703576,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FERROUS_SULFATE",
        "predisposition": "FERROUS SULFATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 252,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6478371,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLUOXETINE",
        "predisposition": "FLUOXETINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 168,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4329323,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FOLEX.2FFORIC.2FFOROL_CD",
        "predisposition": "FOLEX/FORIC/FOROL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 102,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2641444,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLIMEPIRIDE",
        "predisposition": "GLIMEPIRIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 519,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 13417932,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULINS_SYRINGE",
        "predisposition": "INSULINS SYRINGE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 145,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4337369,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IPRATROPIUM_BROMIDE",
        "predisposition": "IPRATROPIUM BROMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 479,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 12357494,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ISOCORT.2FTEVADERM_CD",
        "predisposition": "ISOCORT/TEVADERM CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 128,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3839041,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LACTULOSE",
        "predisposition": "LACTULOSE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 330,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8522175,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LINAGLIPTIN",
        "predisposition": "LINAGLIPTIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 91,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2353812,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MINOCYCLINE",
        "predisposition": "MINOCYCLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 19,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 565578,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MINOXIDIL",
        "predisposition": "MINOXIDIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 27,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 804164,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OMEGA.2D3.2DTRIGLYCERIDES_CD",
        "predisposition": "OMEGA-3-TRIGLYCERIDES CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 188,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4865173,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POTASSIUM_CHLORIDE",
        "predisposition": "POTASSIUM CHLORIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 160,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4770526,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SACCHARIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 90,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2316343,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SLOW_FE_FOLIC.2FFERROGRAD_FOLIC_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 867,
        "predisposition_and_risk": 260,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7752553,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.T2D.SGLT2i",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.12,
        "risk_count": 811,
        "predisposition_and_risk": 252,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6488601,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ADALIMUMAB",
        "predisposition": "ADALIMUMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 33,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 857152,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ALFACALCIDOL",
        "predisposition": "ALFACALCIDOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 320,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8346064,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AMIODARONE",
        "predisposition": "AMIODARONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 418,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10914224,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.APIXABAN",
        "predisposition": "APIXABAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 139,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3634007,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BACK_BRACE",
        "predisposition": "BACK BRACE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 73,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1905334,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BETAHISTINE",
        "predisposition": "BETAHISTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 162,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4210482,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BRONCHO_D_CD",
        "predisposition": "BRONCHO D CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 171,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4437137,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BRONCHO_D_CD",
        "predisposition": "BRONCHO D CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 207,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6236837,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CAPTOPRIL",
        "predisposition": "CAPTOPRIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 257,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6684127,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CAPTOPRIL",
        "predisposition": "CAPTOPRIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 246,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7419142,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CETRIMIDE",
        "predisposition": "CETRIMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 13,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 392737,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CHAMOMILE",
        "predisposition": "CHAMOMILE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 18,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 542163,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHLORHEXIDINE",
        "predisposition": "CHLORHEXIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 154,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4022661,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLEAN.2DEARS_CD",
        "predisposition": "CLEAN-EARS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 30,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 782975,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENCYPALMED_CD",
        "predisposition": "ENCYPALMED CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 139,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3629400,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ERYTHROMYCIN",
        "predisposition": "ERYTHROMYCIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 23,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 601283,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ESCITALOPRAM",
        "predisposition": "ESCITALOPRAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 461,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 12006654,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLUCONAZOLE",
        "predisposition": "FLUCONAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 40,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1045577,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FOAM_DRESSING",
        "predisposition": "FOAM DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 93,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2791577,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYALURONIC_ACID",
        "predisposition": "HYALURONIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 211,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6333798,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_DETEMIR",
        "predisposition": "INSULIN DETEMIR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 402,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 12155876,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_PUMPS",
        "predisposition": "INSULIN PUMPS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 214,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5575311,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LEVOCABASTINE",
        "predisposition": "LEVOCABASTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 27,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 705017,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LOPERAMIDE",
        "predisposition": "LOPERAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 321,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9665492,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAGNESIUM_CITRATE",
        "predisposition": "MAGNESIUM CITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 149,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3886629,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METFORMIN_AND_EMPAGLIFLOZIN",
        "predisposition": "METFORMIN AND EMPAGLIFLOZIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 46,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1200755,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METOCLOPRAMIDE",
        "predisposition": "METOCLOPRAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 188,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4875896,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXYBUTYNIN",
        "predisposition": "OXYBUTYNIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 86,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2248826,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PANTOPRAZOLE",
        "predisposition": "PANTOPRAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 184,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5540315,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PNEUMOCOCCUS.2C_PURIFIED_POLYSACHARIDES_ANTIGEN",
        "predisposition": "PNEUMOCOCCUS, PURIFIED POLYSACHARIDES ANTIGEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 102,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2655173,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POVIDONE",
        "predisposition": "POVIDONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 32,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 963075,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SENNA_LEAVES",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 59,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1781080,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.T2D.INSULIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 704,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 21144979,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TACROLIMUS",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 125,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3766303,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL_.2D_DORZOLAMIDE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 312,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9444730,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIOTROPIUM_BROMIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 867,
        "predisposition_and_risk": 166,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5008314,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TOLTERODINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 109,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2830782,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.URINE_TEST_STRIPS",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 488,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 12756671,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ZOPICLONE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.11,
        "risk_count": 811,
        "predisposition_and_risk": 292,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 7612904,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACARBOSE",
        "predisposition": "ACARBOSE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 247,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6517782,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALENDRONIC_ACID.2C_AND_COLECALCIFEROL",
        "predisposition": "ALENDRONIC ACID, AND COLECALCIFEROL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 217,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6598326,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALFACALCIDOL",
        "predisposition": "ALFACALCIDOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 314,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9578762,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALKASOLVE_CD",
        "predisposition": "ALKASOLVE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 18,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 548943,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BETAMETHASONE",
        "predisposition": "BETAMETHASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 176,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4640590,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CANDESARTAN",
        "predisposition": "CANDESARTAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 301,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9132620,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CARVEDILOL",
        "predisposition": "CARVEDILOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 332,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 10087589,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CICLOPIROX",
        "predisposition": "CICLOPIROX",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 147,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4479012,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CILAZAPRIL",
        "predisposition": "CILAZAPRIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 410,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10778790,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.COAG.NO_CLEXANE_40MG",
        "predisposition": "COAG (NO CLEXANE 40MG)",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 642,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 16868780,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.COAG.NO_CLEXANE_40MG",
        "predisposition": "COAG (NO CLEXANE 40MG)",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 601,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 18337008,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CODEINE_AND_PARACETAMOL",
        "predisposition": "CODEINE AND PARACETAMOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 323,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9850021,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DAPAGLIFLOZIN",
        "predisposition": "DAPAGLIFLOZIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 103,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3144162,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXAMYCIN.2FDETHAMYCIN_CD",
        "predisposition": "DEXAMYCIN/DETHAMYCIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 234,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7148595,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DILTIAZEM",
        "predisposition": "DILTIAZEM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 174,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4591335,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DULOXETINE",
        "predisposition": "DULOXETINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 384,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10077124,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ESOMEPRAZOLE",
        "predisposition": "ESOMEPRAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 243,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6392753,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EXAMINATION_GLOVES",
        "predisposition": "EXAMINATION GLOVES",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 28,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 738448,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FELODIPINE",
        "predisposition": "FELODIPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 162,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4257538,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUTICASONE",
        "predisposition": "FLUTICASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 374,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11355005,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FUROSEMIDE",
        "predisposition": "FUROSEMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 664,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 17495249,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INDACATEROL",
        "predisposition": "INDACATEROL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 59,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1554336,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_ASPART",
        "predisposition": "INSULIN ASPART",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 403,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 12248334,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_GLARGINE",
        "predisposition": "INSULIN GLARGINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 557,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 16903148,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IPRATROPIUM_BROMIDE",
        "predisposition": "IPRATROPIUM BROMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 469,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 14240757,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LEVODOPA_AND_DECARBOXYLASE_INHIBITOR",
        "predisposition": "LEVODOPA AND DECARBOXYLASE INHIBITOR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 174,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4574810,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LITHIUM",
        "predisposition": "LITHIUM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 80,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2100094,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LORNOXICAM",
        "predisposition": "LORNOXICAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 196,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5938076,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LUBRICANS_CD",
        "predisposition": "LUBRICANS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 14,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 426423,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAALOX_CD",
        "predisposition": "MAALOX CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 94,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2860225,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAXITROL_CD",
        "predisposition": "MAXITROL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 238,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7234426,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METFORMIN_AND_SITAGLIPTIN_CD",
        "predisposition": "METFORMIN AND SITAGLIPTIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 556,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 14552694,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MONTELUKAST",
        "predisposition": "MONTELUKAST",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 130,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3940687,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MUPIROCIN",
        "predisposition": "MUPIROCIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 216,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6549945,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NYSTATIN",
        "predisposition": "NYSTATIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 45,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1363630,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXYCODONE_AND_PARACETAMOL",
        "predisposition": "OXYCODONE AND PARACETAMOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 242,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6388401,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POLYACRYLIC_ACID",
        "predisposition": "POLYACRYLIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 65,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1701396,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POVIDONE_COMP_CD",
        "predisposition": "POVIDONE COMP CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 76,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2303359,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PREGABALIN",
        "predisposition": "PREGABALIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 451,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 11828994,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROCTO.2DGLYVENOL_CD",
        "predisposition": "PROCTO-GLYVENOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 279,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8510296,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.REPAGLINIDE",
        "predisposition": "REPAGLINIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 589,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 15492934,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SENNOSIDES_A.2BB",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 67,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2029013,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SULFASALAZINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 64,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1937723,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TALC",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 19,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 499295,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 185,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4858100,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TOCOPHERYL_.28VITAMIN_E.29",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 378,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 9927225,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.URSODEOXYCHOLIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 867,
        "predisposition_and_risk": 127,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3855701,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.WATER_FOR_IRRIGATION",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.1,
        "risk_count": 811,
        "predisposition_and_risk": 132,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3462057,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ACARBOSE",
        "predisposition": "ACARBOSE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 253,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7775204,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ADALIMUMAB",
        "predisposition": "ADALIMUMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 42,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1284589,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALCOHOL",
        "predisposition": "ALCOHOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 527,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 16105106,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ARIPIPRAZOLE",
        "predisposition": "ARIPIPRAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 13,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 344092,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CEFUROXIME",
        "predisposition": "CEFUROXIME",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 421,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 11191684,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CILAZAPRIL.2DHYDROCHLOROTHIAZIDE_CD",
        "predisposition": "CILAZAPRIL-HYDROCHLOROTHIAZIDE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 401,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 12255355,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLINDAMYCIN",
        "predisposition": "CLINDAMYCIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 91,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2413743,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLOTRIMAZOLE",
        "predisposition": "CLOTRIMAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 158,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4177668,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CODEINE_AND_NON.2DOPIOID_ANALGESICS",
        "predisposition": "CODEINE AND NON-OPIOID ANALGESICS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 503,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 15378358,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DEXAMYCIN.2FDETHAMYCIN_CD",
        "predisposition": "DEXAMYCIN/DETHAMYCIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 190,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5061450,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOXAZOSIN",
        "predisposition": "DOXAZOSIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 543,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 16634910,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ETANERCEPT",
        "predisposition": "ETANERCEPT",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 33,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 877249,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HEPATITIS_B_VACCINE",
        "predisposition": "HEPATITIS B VACCINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 47,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1444392,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROAGISTEN_CD",
        "predisposition": "HYDROAGISTEN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 156,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4795689,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_GLULISINE",
        "predisposition": "INSULIN GLULISINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 303,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9278814,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_HUMALOG_MIX_CD",
        "predisposition": "INSULIN HUMALOG MIX CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 173,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5306089,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_PEN_LANCETS",
        "predisposition": "INSULIN PEN LANCETS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 601,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 18444515,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_PUMPS",
        "predisposition": "INSULIN PUMPS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 173,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5313432,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_SYRINGE",
        "predisposition": "INSULIN SYRINGE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 46,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1221219,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ISOSORBIDE_MONONITRATE",
        "predisposition": "ISOSORBIDE MONONITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 316,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9721596,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KETOTIFEN",
        "predisposition": "KETOTIFEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 39,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1193580,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEFLUNOMIDE",
        "predisposition": "LEFLUNOMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 26,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 796378,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LETROZOLE",
        "predisposition": "LETROZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 165,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5051389,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEVOMEPROMAZINE",
        "predisposition": "LEVOMEPROMAZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 51,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1566832,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LYTEERS.2FV.2DTEARS",
        "predisposition": "LYTEERS/V-TEARS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 137,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3628979,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MEBENDAZOLE",
        "predisposition": "MEBENDAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 18,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 476951,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MIANSERIN",
        "predisposition": "MIANSERIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 71,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2177364,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OTC",
        "predisposition": "OTC",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 58,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1787936,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYCODONE_AND_PARACETAMOL",
        "predisposition": "OXYCODONE AND PARACETAMOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 235,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7216569,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.QUETIAPINE",
        "predisposition": "QUETIAPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 139,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4284452,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SELENIUM_COMPOUNDS",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 53,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1404487,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SERETIDE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 421,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 12863550,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SOLIFENACIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 139,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4250720,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TEVACUTAN.2FPOLYCUTAN_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 224,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5918954,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THEOPHYLLINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 176,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4664546,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VERAPAMIL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 315,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8375504,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VERAPAMIL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 867,
        "predisposition_and_risk": 373,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11461878,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.WARFARIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.09,
        "risk_count": 811,
        "predisposition_and_risk": 587,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 15502243,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BETAHISTINE",
        "predisposition": "BETAHISTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 285,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8787517,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BLOOD_PRESSURE_MONITOR",
        "predisposition": "BLOOD PRESSURE MONITOR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 84,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2252786,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALCIPOTRIOL",
        "predisposition": "CALCIPOTRIOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 16,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 426790,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CIPROFLOXACIN",
        "predisposition": "CIPROFLOXACIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 384,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11887314,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLOMIPRAMINE",
        "predisposition": "CLOMIPRAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 97,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2994470,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLONIDINE",
        "predisposition": "CLONIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 256,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7929345,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLOPIDOGREL",
        "predisposition": "CLOPIDOGREL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 540,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 16745379,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIFLUCORTOLONE",
        "predisposition": "DIFLUCORTOLONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 98,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2630865,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIGOXIN",
        "predisposition": "DIGOXIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 194,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6001596,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENALAPRIL_AND_LERCANIDIPINE",
        "predisposition": "ENALAPRIL AND LERCANIDIPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 185,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4952756,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENSURE_PLUS_CD",
        "predisposition": "ENSURE PLUS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 169,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5213234,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYALURONIC_ACID.2DLACTIC_ACID.2DUREA_CD",
        "predisposition": "HYALURONIC ACID-LACTIC ACID-UREA CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 43,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1155522,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INDACATEROL_AND_GLYCOPYRRONIUM_BROMIDE",
        "predisposition": "INDACATEROL AND GLYCOPYRRONIUM BROMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 29,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 778779,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_PEN_LANCETS",
        "predisposition": "INSULIN PEN LANCETS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 618,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 16546383,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN.2C_ISOPHANE.28NPH.29",
        "predisposition": "INSULIN, ISOPHANE(NPH)",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 190,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5107988,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LACTULOSE",
        "predisposition": "LACTULOSE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 308,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9527048,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LIXISENATIDE",
        "predisposition": "LIXISENATIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 21,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 561762,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LOMEFLOXACIN",
        "predisposition": "LOMEFLOXACIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 24,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 742162,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MEDIUM",
        "predisposition": "MEDIUM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 18,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 480954,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MILNACIPRAN",
        "predisposition": "MILNACIPRAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 52,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1609410,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NABUMETONE",
        "predisposition": "NABUMETONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 63,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1947421,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NITROFURANTOIN",
        "predisposition": "NITROFURANTOIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 267,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8238032,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PARACETAMOL.2C_COMBINATIONS_EXCL.2E_PSYCHOLEPTIC",
        "predisposition": "PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTIC",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 55,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1472870,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PHENAZOPYRIDINE",
        "predisposition": "PHENAZOPYRIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 91,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2429933,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PICO.2DSALAX.2FCITRAFLEET",
        "predisposition": "PICO-SALAX/CITRAFLEET",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 167,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5194439,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROMETHAZINE",
        "predisposition": "PROMETHAZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 137,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4226165,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PSEUDOEPHRINE",
        "predisposition": "PSEUDOEPHRINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 54,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1451923,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SPIRONOLACTONE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 441,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 13683574,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.STOMA",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 132,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3528056,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SULPIRIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 222,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6890219,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SYMBICORT.2FDUORESP",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 316,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9777934,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.T2D.GLP1_RA",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 380,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10165647,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.T2D.TZD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 255,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6806758,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TOBRAMYCIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 56,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1740041,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TOPIRAMATE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 92,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2853758,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRANEXAMIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 293724,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRAVOPROST",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 103,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2753933,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRAZODONE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 811,
        "predisposition_and_risk": 76,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2037917,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRIAMCINOLONE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 137,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4261683,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRIDERM_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 171,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5273477,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.WARFARIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.08,
        "risk_count": 867,
        "predisposition_and_risk": 509,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 15803628,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ALCOHOL",
        "predisposition": "ALCOHOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 478,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 12867176,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BETAMETHASONE_DIPR.2E.2DCALCIPOTRIOL",
        "predisposition": "BETAMETHASONE DIPR.-CALCIPOTRIOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 67,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1802405,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BISACODYL",
        "predisposition": "BISACODYL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 615,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 19189039,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CANDESARTAN",
        "predisposition": "CANDESARTAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 316,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8530181,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CIPROFIBRATE",
        "predisposition": "CIPROFIBRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 171,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4610187,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CIPROFLOXACIN",
        "predisposition": "CIPROFLOXACIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 385,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10425406,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.COMPLEX_WOUNDS_DRESSSING",
        "predisposition": "COMPLEX WOUNDS DRESSSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 494,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 15396179,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DOMPERIDONE",
        "predisposition": "DOMPERIDONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 86,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2330419,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DOXEPIN",
        "predisposition": "DOXEPIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 23,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 620114,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DURATEARS_CD",
        "predisposition": "DURATEARS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 21,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 567184,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EMPAGLIFLOZIN",
        "predisposition": "EMPAGLIFLOZIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 126,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3399565,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENALAPRIL_AND_LERCANIDIPINE",
        "predisposition": "ENALAPRIL AND LERCANIDIPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 153,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4761683,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ESOMEPRAZOLE",
        "predisposition": "ESOMEPRAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 363,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11395484,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FERROUS_CALCIUM_CITRATE",
        "predisposition": "FERROUS CALCIUM CITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 71,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2228765,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUCONAZOLE",
        "predisposition": "FLUCONAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 74,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2315327,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FOLIC_ACID",
        "predisposition": "FOLIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 541,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 16944621,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GAUZE_DRESSING",
        "predisposition": "GAUZE DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 450,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 12133627,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLIBENCLAMIDE",
        "predisposition": "GLIBENCLAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 572,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 17893645,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLYCERIN_CD",
        "predisposition": "GLYCERIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 179,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4835811,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INHALER_PARTS",
        "predisposition": "INHALER PARTS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 33,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 895369,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INHALER_PARTS",
        "predisposition": "INHALER PARTS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 42,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1317305,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_DEGLUDEC",
        "predisposition": "INSULIN DEGLUDEC",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 45,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1412420,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_LISPRO",
        "predisposition": "INSULIN LISPRO",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 228,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6151640,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KETOCONAZOLE",
        "predisposition": "KETOCONAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 81,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2542986,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LIRAGLUTIDE",
        "predisposition": "LIRAGLUTIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 325,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8781710,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LITHIUM",
        "predisposition": "LITHIUM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 94,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2950051,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHYLPHENIDATE",
        "predisposition": "METHYLPHENIDATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 45,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1216729,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MIDRO.2DTEA_CD",
        "predisposition": "MIDRO-TEA CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 16,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 433779,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MOMETASONE",
        "predisposition": "MOMETASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 148,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4611107,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MUPIROCIN",
        "predisposition": "MUPIROCIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 178,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4814856,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NIRVAXAL_CD",
        "predisposition": "NIRVAXAL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 56,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1746036,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OFLOXACIN",
        "predisposition": "OFLOXACIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 324,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8794956,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PAROXETINE",
        "predisposition": "PAROXETINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 309,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8364355,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PNEUMOCOCCUS.2C_PURIFIED_POLYSACHARIDES_ANTIGEN",
        "predisposition": "PNEUMOCOCCUS, PURIFIED POLYSACHARIDES ANTIGEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 98,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3054919,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROPAFENONE",
        "predisposition": "PROPAFENONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 162,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4384895,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ROKAL_CD",
        "predisposition": "ROKAL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 16,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 433417,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ROPINIROLE",
        "predisposition": "ROPINIROLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 36,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1124438,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ROSIGLITAZONE",
        "predisposition": "ROSIGLITAZONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 244,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6582644,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ROSIGLITAZONE",
        "predisposition": "ROSIGLITAZONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 241,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7537429,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SLOW_FE_FOLIC.2FFERROGRAD_FOLIC_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 209,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5668330,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TERPENES_COMP_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 46,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1444852,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL.2DBRIMONIDINE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 34,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1059409,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIOTROPIUM_BROMIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 285,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 7691285,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TROSPIUM",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 110,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2965122,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VALERIANAE_RADIX",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 811,
        "predisposition_and_risk": 56,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1507692,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VALSARTAN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 604,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 18831207,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VERUCID.2FVERRUMAL_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.07,
        "risk_count": 867,
        "predisposition_and_risk": 46,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1442051,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACAMOL_TSINUN.2FDEXAMOL_SINUS_CD",
        "predisposition": "ACAMOL TSINUN/DEXAMOL SINUS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 166,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4534196,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AMANTADINE",
        "predisposition": "AMANTADINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 95,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2602091,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AMIODARONE",
        "predisposition": "AMIODARONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 263,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8316521,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AQUEOUS_CREAM_CD",
        "predisposition": "AQUEOUS CREAM CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 291,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9165747,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASCORBIC_ACID_.28VIT_C.29",
        "predisposition": "ASCORBIC ACID (VIT C)",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 119,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3761695,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AVENE.2FULTRASOL.2FSKIN_GAURD_CD",
        "predisposition": "AVENE/ULTRASOL/SKIN GAURD CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 142,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4471721,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BACLOFEN",
        "predisposition": "BACLOFEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 114,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3119541,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALCIUM_CARBONATE",
        "predisposition": "CALCIUM CARBONATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 287,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 7827082,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CELECOXIB",
        "predisposition": "CELECOXIB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 171,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5401382,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CINNARIZINE",
        "predisposition": "CINNARIZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 117,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3179405,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CITALOPRAM",
        "predisposition": "CITALOPRAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 565,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 17818238,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CRANBERRY_CONC.2ECD",
        "predisposition": "CRANBERRY CONC.CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 80,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2524869,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CROMOGLICIC_ACID",
        "predisposition": "CROMOGLICIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 21,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 574511,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CYANOCOBALAMINE",
        "predisposition": "CYANOCOBALAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 479,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 13078387,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXPANTHENOL",
        "predisposition": "DEXPANTHENOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 62,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1962358,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIABETES_LANCETS",
        "predisposition": "DIABETES LANCETS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 206,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5594027,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DRESSING",
        "predisposition": "DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 139,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4400148,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FERRIFOL_CD",
        "predisposition": "FERRIFOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 110,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3481020,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUVOXAMINE",
        "predisposition": "FLUVOXAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 95,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2994547,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FOAM_DRESSING",
        "predisposition": "FOAM DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 112,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3041812,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FORMOTEROL",
        "predisposition": "FORMOTEROL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 141,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3864089,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLIMEPIRIDE",
        "predisposition": "GLIMEPIRIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 470,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 14856843,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROQUINONE",
        "predisposition": "HYDROQUINONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 19,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 600256,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IMATINIB",
        "predisposition": "IMATINIB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 17,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 536069,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_GLARGINE",
        "predisposition": "INSULIN GLARGINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 581,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 15837440,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ISOSORBIDE_DINITRATE",
        "predisposition": "ISOSORBIDE DINITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 183,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5761994,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KALURIL_CD",
        "predisposition": "KALURIL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 103,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3253027,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LATANOPROST",
        "predisposition": "LATANOPROST",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 307,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9689365,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEVOTHYROXINE_SODIUM",
        "predisposition": "LEVOTHYROXINE SODIUM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 711,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 22535903,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LIRAGLUTIDE",
        "predisposition": "LIRAGLUTIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 352,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11111125,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LOSARTAN.2DHYDROCHLOROTHIAZIDE_CD",
        "predisposition": "LOSARTAN-HYDROCHLOROTHIAZIDE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 509,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 16073580,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MICONAZOLE",
        "predisposition": "MICONAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 179,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5649147,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MIZOLASTINE",
        "predisposition": "MIZOLASTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 32,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1005460,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MYCOPHENOLIC_ACID",
        "predisposition": "MYCOPHENOLIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 237,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6438639,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NITROFURANTOIN",
        "predisposition": "NITROFURANTOIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 45,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1226071,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ORACORT_E_CD",
        "predisposition": "ORACORT E CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 142,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4472871,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PAPAVERINE",
        "predisposition": "PAPAVERINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 102,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2782400,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PENTOXIFYLLINE",
        "predisposition": "PENTOXIFYLLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 68,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2140533,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PERICIAZINE",
        "predisposition": "PERICIAZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 299057,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RANITIDINE",
        "predisposition": "RANITIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 235,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6386301,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RIVASTIGMINE",
        "predisposition": "RIVASTIGMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 27,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 849344,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SALBUTAMOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 504,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 15932992,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.T2D.INSULIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 671,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 18307931,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.T2D.SU",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 693,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 21906856,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.T2D.TZD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 246,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7794326,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TACROLIMUS",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 221,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6027345,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TADALAFIL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 375,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10261346,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRAMADOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 409,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 11179102,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRAMADOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 485,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 15288126,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRIBEMIN.2FBTRIVIT_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 661,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 20840804,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TROPICAMIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 299288,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VALERIANAE_RADIX",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 146,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4600858,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VALSARTAN.2DAMLODIPINE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 328,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 10310074,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ZOLPIDEM",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.06,
        "risk_count": 867,
        "predisposition_and_risk": 471,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 14838610,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BETACORTEN.2DG.2FCELESTODERM.2DG_CD",
        "predisposition": "BETACORTEN-G/CELESTODERM-G CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 155,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4251094,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BIFONAZOLE",
        "predisposition": "BIFONAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 231,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6391369,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BIMATOPROST",
        "predisposition": "BIMATOPROST",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 75,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2061927,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BISOPROLOL",
        "predisposition": "BISOPROLOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 710,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 22602675,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BRIMONIDINE",
        "predisposition": "BRIMONIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 200,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6376205,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALAMINE_LOTION_CD",
        "predisposition": "CALAMINE LOTION CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 22,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 604282,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CARVEDILOL",
        "predisposition": "CARVEDILOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 553,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 15263835,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CEFALEXIN",
        "predisposition": "CEFALEXIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 260,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 7162109,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLOBETASONE",
        "predisposition": "CLOBETASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 38,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1205711,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.COMPLEX_WOUNDS_DRESSSING",
        "predisposition": "COMPLEX WOUNDS DRESSSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 480,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 13263951,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DONEPEZIL",
        "predisposition": "DONEPEZIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 32,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1023091,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DOXAZOSIN",
        "predisposition": "DOXAZOSIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 694,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 19117477,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DULOXETINE",
        "predisposition": "DULOXETINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 425,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 13541892,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ELASTIC_BANDAGE",
        "predisposition": "ELASTIC BANDAGE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 86,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2370073,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EMOL.2FAQUAPHOR_CD",
        "predisposition": "EMOL/AQUAPHOR CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 247,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7855934,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ETANERCEPT",
        "predisposition": "ETANERCEPT",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 46,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1461846,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FAMOTIDINE",
        "predisposition": "FAMOTIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 635,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 17530127,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FERROUS_SULFATE",
        "predisposition": "FERROUS SULFATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 245,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7837812,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FESOTERODINE",
        "predisposition": "FESOTERODINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 80,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2558596,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GARLIC",
        "predisposition": "GARLIC",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 14,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 446670,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GAUZE_DRESSING",
        "predisposition": "GAUZE DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 499,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 15837600,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYCOMYCIN_CD",
        "predisposition": "HYCOMYCIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 37,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1022146,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LERCANIDIPINE",
        "predisposition": "LERCANIDIPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 645,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 17842539,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEVODOPA_AND_DECARBOXYLASE_INHIBITOR",
        "predisposition": "LEVODOPA AND DECARBOXYLASE INHIBITOR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 117,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3734809,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MACROGOL",
        "predisposition": "MACROGOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 105,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2898745,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MEROKEN_NEW_CD",
        "predisposition": "MEROKEN NEW CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 78,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2491079,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHOTREXATE",
        "predisposition": "METHOTREXATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 79,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2180527,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METHYLPREDNISOLONE",
        "predisposition": "METHYLPREDNISOLONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 117,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3718028,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METOPROLOL",
        "predisposition": "METOPROLOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 635,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 17523496,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METRONIDAZOLE",
        "predisposition": "METRONIDAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 95,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2626554,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MIRTAZAPINE",
        "predisposition": "MIRTAZAPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 261,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8306876,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NUSSIDEX.2FHISTADEX_CD",
        "predisposition": "NUSSIDEX/HISTADEX CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 185,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5112162,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NYSTATIN",
        "predisposition": "NYSTATIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 35,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 962242,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXALIPLATIN",
        "predisposition": "OXALIPLATIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 17,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 470120,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROPOXYPHENE.2DPARACETAMOL",
        "predisposition": "PROPOXYPHENE-PARACETAMOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 518,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 16455443,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RETINOL",
        "predisposition": "RETINOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 11,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 349207,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RIBAVIRIN",
        "predisposition": "RIBAVIRIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 304388,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SENNOSIDES_A.2BB",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 44,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1213850,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SODIUM_CHLORIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 246,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6747852,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SPASMALGIN_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 80,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2201795,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.T2D.GLP1_RA",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 401,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 12821448,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TEARS_NATURALE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 59,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1623842,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL.2DLATANOPROST",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 96,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2651733,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TUSSOPHEDRIN_NEW_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 38,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1206519,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VILANTEROL_AND_FLUTICASONE_FUROATE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 867,
        "predisposition_and_risk": 87,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2774772,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.XYLOMETAZOLINE.2DMENTHOL_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 182,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5026205,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ZOLPIDEM",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.05,
        "risk_count": 811,
        "predisposition_and_risk": 347,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 9577492,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASCORBIC_ACID.2DROSE_HIPS_CD",
        "predisposition": "ASCORBIC ACID-ROSE HIPS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 96,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3076895,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ATROPINE",
        "predisposition": "ATROPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 17,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 548219,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BETHAMETHASONE",
        "predisposition": "BETHAMETHASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 288,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9278055,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BISACODYL",
        "predisposition": "BISACODYL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 480,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 13352570,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BRONCHOLATE_FORTE_CD",
        "predisposition": "BRONCHOLATE FORTE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 76,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2442684,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BUPROPION",
        "predisposition": "BUPROPION",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 60,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1929390,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CARBAMAZEPINE",
        "predisposition": "CARBAMAZEPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 295,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9482535,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CARBAMIDE.2D_COMBINATIONS_CD",
        "predisposition": "CARBAMIDE- COMBINATIONS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 210,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5844744,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CATHETER_SUPP.2E",
        "predisposition": "CATHETER SUPP.",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 68,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1886962,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHOLECALCIFEROL",
        "predisposition": "CHOLECALCIFEROL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 599,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 16652628,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CINNARIZINE",
        "predisposition": "CINNARIZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 214,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6874494,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLONAZEPAM",
        "predisposition": "CLONAZEPAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 501,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 13964007,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLOPIDOGREL",
        "predisposition": "CLOPIDOGREL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 665,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 18566448,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.COLDEX.2FTEVA.2DCOLD_CD",
        "predisposition": "COLDEX/TEVA-COLD CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 116,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3240628,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIAZEPAM",
        "predisposition": "DIAZEPAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 322,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8977405,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIPYRIDAMOLE",
        "predisposition": "DIPYRIDAMOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 76,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2434658,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENCYPALMED_CD",
        "predisposition": "ENCYPALMED CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 208,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6710502,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FAMOTIDINE",
        "predisposition": "FAMOTIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 643,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 20758287,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FOLIC_ACID",
        "predisposition": "FOLIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 575,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 15937504,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLIBENCLAMIDE",
        "predisposition": "GLIBENCLAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 595,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 16502907,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLUCOMETER_STRIPS",
        "predisposition": "GLUCOMETER STRIPS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 709,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 22714623,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLUCOSAMINE.2BCHONDROIT.2E_CD",
        "predisposition": "GLUCOSAMINE+CHONDROIT. CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 45,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1256612,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HALOPERIDOL",
        "predisposition": "HALOPERIDOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 148,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4128526,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HALOPERIDOL",
        "predisposition": "HALOPERIDOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 132,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4237012,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HAND_BRACE",
        "predisposition": "HAND BRACE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 82,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2630847,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_ASPART",
        "predisposition": "INSULIN ASPART",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 429,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 11912474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_NOVOMIX",
        "predisposition": "INSULIN NOVOMIX",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 293,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8179615,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ISOSORBIDE_MONONITRATE",
        "predisposition": "ISOSORBIDE MONONITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 464,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 12896455,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LANSOPRAZOLE",
        "predisposition": "LANSOPRAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 727,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 23311267,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEMOCIN_CD",
        "predisposition": "LEMOCIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 192,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6163627,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LORAZEPAM",
        "predisposition": "LORAZEPAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 427,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 11898948,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LOSARTAN",
        "predisposition": "LOSARTAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 629,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 17514031,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LOSARTAN",
        "predisposition": "LOSARTAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 667,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 21353137,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAALOX_CD",
        "predisposition": "MAALOX CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 76,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2112171,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METOPROLOL",
        "predisposition": "METOPROLOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 560,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 18068013,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MIRTAZAPINE",
        "predisposition": "MIRTAZAPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 241,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6673463,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NITRAZEPAM",
        "predisposition": "NITRAZEPAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 68,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2191558,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PREDNISONE",
        "predisposition": "PREDNISONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 502,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 13998368,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RAMIPRIL.2DHYDROCHLOROTHIAZIDE_CD",
        "predisposition": "RAMIPRIL-HYDROCHLOROTHIAZIDE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 560,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 15585809,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ROSUVASTATIN",
        "predisposition": "ROSUVASTATIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 693,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 19297011,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ROXITHROMYCIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 241,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6719207,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SPIRONOLACTONE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 534,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 14795943,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.T2D.SU",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 685,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 19023483,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 204,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6560798,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRIDERM_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 129,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3593975,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TUSSOPHEDRIN_NEW_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 33,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 919115,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VALSARTAN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 811,
        "predisposition_and_risk": 573,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 15974409,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VIT.2EB12_COMBINATIONS_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 220,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7056102,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ZINCOD_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 36,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1161850,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ZUCLOPENTHIXOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.04,
        "risk_count": 867,
        "predisposition_and_risk": 98,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3137268,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ALLOPURINOL",
        "predisposition": "ALLOPURINOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 584,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 16392436,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AMITRIPTYLINE",
        "predisposition": "AMITRIPTYLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 470,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 15336591,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASCORBIC_ACID.2DPROPOLIS_CD",
        "predisposition": "ASCORBIC ACID-PROPOLIS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 25,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 814650,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BEZAFIBRATE",
        "predisposition": "BEZAFIBRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 673,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 18832516,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BIFONAZOLE",
        "predisposition": "BIFONAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 265,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8565961,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CEFALEXIN",
        "predisposition": "CEFALEXIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 323,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 10531845,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CHARCOAL_MEDICINAL",
        "predisposition": "CHARCOAL MEDICINAL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 86,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2796035,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHLORAMPHENICOL",
        "predisposition": "CHLORAMPHENICOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 335,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 9437928,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CILAZAPRIL",
        "predisposition": "CILAZAPRIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 334,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 10828002,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CODEINE",
        "predisposition": "CODEINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 329,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 10680205,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.COMAGIS_CD",
        "predisposition": "COMAGIS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 43,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1212923,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DERMACOMBIN.2FKENACOMB_CD",
        "predisposition": "DERMACOMBIN/KENACOMB CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 209,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5892451,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIACEREIN",
        "predisposition": "DIACEREIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 66,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1853196,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIRECT_ORAL_ANTI_COAG",
        "predisposition": "DIRECT ORAL ANTO COAG",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 369,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11995756,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DISOPYRAMIDE",
        "predisposition": "DISOPYRAMIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 13,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 420317,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DROSPIRENONE_AND_ETHINYLESTRADIOL",
        "predisposition": "DROSPIRENONE AND ETHINYLESTRADIOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 35,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1135747,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ESCITALOPRAM",
        "predisposition": "ESCITALOPRAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 587,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 19028861,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ETODOLAC",
        "predisposition": "ETODOLAC",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 576,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 18729734,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ETORICOXIB",
        "predisposition": "ETORICOXIB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 409,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 13320360,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EZETIMIBE",
        "predisposition": "EZETIMIBE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 359,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11620035,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FINGER_DRESSING",
        "predisposition": "FINGER DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 50,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1403250,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLUCOMETER_STRIPS",
        "predisposition": "GLUCOMETER STRIPS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 689,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 19291573,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDROGEN_PEROXIDE",
        "predisposition": "HYDROGEN PEROXIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 64,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1790972,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INFLUENZA.2C_INACTIVATED.2C_SPLIT_VIRUS_OR_SURFACE_ANTIGEN",
        "predisposition": "INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 698,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 22774029,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_DETEMIR",
        "predisposition": "INSULIN DETEMIR",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 380,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10717538,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN.2C_ISOPHANE.28NPH.29",
        "predisposition": "INSULIN, ISOPHANE(NPH)",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 179,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5798753,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.KALGARON_CD",
        "predisposition": "KALGARON CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 65,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1826389,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KALGARON_CD",
        "predisposition": "KALGARON CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 86,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2796782,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LANSOPRAZOLE",
        "predisposition": "LANSOPRAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 643,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 18031237,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LERCANIDIPINE",
        "predisposition": "LERCANIDIPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 638,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 20723453,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LINAGLIPTIN",
        "predisposition": "LINAGLIPTIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 46,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1496292,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LOCAL_ANESTHETICS",
        "predisposition": "LOCAL ANESTHETICS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 208,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5824774,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LOSARTAN.2DHYDROCHLOROTHIAZIDE_CD",
        "predisposition": "LOSARTAN-HYDROCHLOROTHIAZIDE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 406,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 11429524,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LYTEERS.2FV.2DTEARS",
        "predisposition": "LYTEERS/V-TEARS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 250,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8133621,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHOXY_POLYETHYLENE_GLYCOL.2DEPOETIN_BETA",
        "predisposition": "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 59,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1653978,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NAPROXEN",
        "predisposition": "NAPROXEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 156,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4379803,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NEOMYCIN",
        "predisposition": "NEOMYCIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 11,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 309368,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PARACETAMOL.2C_COMBINATIONS_EXCL.2E_PSYCHOLEPTIC",
        "predisposition": "PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTIC",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 85,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2752829,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PAROXETINE",
        "predisposition": "PAROXETINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 444,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 14350537,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PHENOXYMETHYLPENICILLIN",
        "predisposition": "PHENOXYMETHYLPENICILLIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 156,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5087730,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PRAVASTATIN",
        "predisposition": "PRAVASTATIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 541,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 15124735,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROCTO.2DGLYVENOL_CD",
        "predisposition": "PROCTO-GLYVENOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 207,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5799537,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROPRANOLOL",
        "predisposition": "PROPRANOLOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 434,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 14125803,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RIVAROXABAN",
        "predisposition": "RIVAROXABAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 126,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3532392,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SALBUTAMOL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 474,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 13337247,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SALMETEROL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 46,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1491336,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.T2D.DPP_4i",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 365,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10202046,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TERBUTALINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 110,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3082273,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TETRYZOLINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 226,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7311860,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL_.2D_DORZOLAMIDE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 332,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 9304715,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL.2DBIMATOPROST_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 811,
        "predisposition_and_risk": 16,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 447582,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.WHITE_SOFT_PARAFFIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.03,
        "risk_count": 867,
        "predisposition_and_risk": 101,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3277130,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ACETYLCYSTEINE",
        "predisposition": "ACETYLCYSTEINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 373,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 12271266,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ACTIVELLE_CD",
        "predisposition": "ACTIVELLE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 278,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9124475,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ALFUZOSIN",
        "predisposition": "ALFUZOSIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 710,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 20122094,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ANESTHETIC.2FOTIDIN_CD",
        "predisposition": "ANESTHETIC/OTIDIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 134,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4395621,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AQUEOUS_CREAM_CD",
        "predisposition": "AQUEOUS CREAM CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 197,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5602676,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ATORVASTATIN",
        "predisposition": "ATORVASTATIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 783,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 22246956,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BACLOFEN",
        "predisposition": "BACLOFEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 78,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2551155,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BEN.2DGAY_CD",
        "predisposition": "BEN-GAY CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 70,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1993367,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BETACORTEN.2DG.2FCELESTODERM.2DG_CD",
        "predisposition": "BETACORTEN-G/CELESTODERM-G CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 179,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5869464,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BEVACIZUMAB",
        "predisposition": "BEVACIZUMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 18,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 589859,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BIPERIDEN",
        "predisposition": "BIPERIDEN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 186,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6072231,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BISOPROLOL",
        "predisposition": "BISOPROLOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 703,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 19860955,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BROMOCRIPTINE",
        "predisposition": "BROMOCRIPTINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 13,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 370305,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BROTIZOLAM",
        "predisposition": "BROTIZOLAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 616,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 17393452,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALCIUM_CARBONATE",
        "predisposition": "CALCIUM CARBONATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 362,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11907461,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CARBAMIDE.2D_COMBINATIONS_CD",
        "predisposition": "CARBAMIDE- COMBINATIONS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 260,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8509523,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CARBOCISTEINE",
        "predisposition": "CARBOCISTEINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 330,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 9377452,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CERUMOL_CD",
        "predisposition": "CERUMOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 22,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 721427,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CETIRIZINE",
        "predisposition": "CETIRIZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 164,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5376372,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLOBETASOL",
        "predisposition": "CLOBETASOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 198,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5614311,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLONAZEPAM",
        "predisposition": "CLONAZEPAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 547,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 17995334,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.COLCHICINE",
        "predisposition": "COLCHICINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 319,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 9044147,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CYANOCOBALAMINE",
        "predisposition": "CYANOCOBALAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 524,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 17130859,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DERMACOMBIN.2FKENACOMB_CD",
        "predisposition": "DERMACOMBIN/KENACOMB CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 349,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11466764,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DESOREN.2FDEXOTIC_CD",
        "predisposition": "DESOREN/DEXOTIC CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 237,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7777043,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXAMOL_COLD_CD",
        "predisposition": "DEXAMOL COLD CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 216,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7099511,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIACEREIN",
        "predisposition": "DIACEREIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 235,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7728204,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EXAMINATION_GLOVES",
        "predisposition": "EXAMINATION GLOVES",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 35,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1143867,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EZETIMIBE",
        "predisposition": "EZETIMIBE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 432,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 12197573,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GENTAMICIN",
        "predisposition": "GENTAMICIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 91,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2579722,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLUCOMETER",
        "predisposition": "GLUCOMETER",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 244,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7985738,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HAND_BRACE",
        "predisposition": "HAND BRACE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 56,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1592949,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HTN.ARB",
        "predisposition": "HTN ARB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 827,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 27123642,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INFLIXIMAB",
        "predisposition": "INFLIXIMAB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 18,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 590381,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_SOLUBLE_.28HUMAN.29",
        "predisposition": "INSULIN SOLUBLE (HUMAN)",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 132,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3747293,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_SYRINGE",
        "predisposition": "INSULIN SYRINGE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 61,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2001476,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LACRIMOL_CD",
        "predisposition": "LACRIMOL CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 310,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 10195020,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LATANOPROST",
        "predisposition": "LATANOPROST",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 287,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8168567,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LIDOCAINE",
        "predisposition": "LIDOCAINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 50,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1421026,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LORATADINE",
        "predisposition": "LORATADINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 325,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 10647947,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MACROGOL",
        "predisposition": "MACROGOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 119,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3910325,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAGNESIUM_CITRATE",
        "predisposition": "MAGNESIUM CITRATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 157,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5166746,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAPROTILINE",
        "predisposition": "MAPROTILINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 15,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 426757,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MERFEN_CD",
        "predisposition": "MERFEN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 96,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3158785,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NIFEDIPINE",
        "predisposition": "NIFEDIPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 501,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 16437822,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ORACORT_E_CD",
        "predisposition": "ORACORT E CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 80,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2270528,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYBUTYNIN",
        "predisposition": "OXYBUTYNIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 148,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4873796,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POVIDONE.2DIODINE",
        "predisposition": "POVIDONE-IODINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 255,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 7204329,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PREDNISOLONE",
        "predisposition": "PREDNISOLONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 93,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3064685,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RAMIPRIL",
        "predisposition": "RAMIPRIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 776,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 21974942,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.REBOXETINE",
        "predisposition": "REBOXETINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 35,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 995664,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RISPERIDONE",
        "predisposition": "RISPERIDONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 129,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4250320,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SELF_CATHETER",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 25,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 708074,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SERETIDE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 390,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 11083131,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TOPISALEN_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 47,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1548278,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.URINE_BAG",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 175,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4964983,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.URINE_TEST_STRIPS",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 432,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 14124896,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VITAMIN_A.2BD_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 867,
        "predisposition_and_risk": 17,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 555525,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ZINC_SULFATE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.02,
        "risk_count": 811,
        "predisposition_and_risk": 17,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 483777,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AMLODIPINE",
        "predisposition": "AMLODIPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 809,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 26861434,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ASCORBIC_ACID_AND_CALCIUM_CD",
        "predisposition": "ASCORBIC ACID AND CALCIUM CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 19,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 541820,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ASPIRIN.2DLYSINE_ACETYLSALICYLATE",
        "predisposition": "ASPIRIN-LYSINE ACETYLSALICYLATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 131,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3753942,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BROTIZOLAM",
        "predisposition": "BROTIZOLAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 699,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 23139830,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BUDESONIDE",
        "predisposition": "BUDESONIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 217,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7216994,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CAPSAICIN",
        "predisposition": "CAPSAICIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 105,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3463637,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CEFUROXIME",
        "predisposition": "CEFUROXIME",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 546,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 18145304,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CETIRIZINE",
        "predisposition": "CETIRIZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 109,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3126133,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CHOLECALCIFEROL",
        "predisposition": "CHOLECALCIFEROL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 816,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 27007054,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CITALOPRAM",
        "predisposition": "CITALOPRAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 417,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 11896656,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLARITHROMYCIN",
        "predisposition": "CLARITHROMYCIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 55,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1569807,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLINDAMYCIN",
        "predisposition": "CLINDAMYCIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 124,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4124720,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.COMAGIS_CD",
        "predisposition": "COMAGIS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 72,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2374376,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DESLORATADINE",
        "predisposition": "DESLORATADINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 172,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5699180,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIRECT_ORAL_ANTI_COAG",
        "predisposition": "DIRECT ORAL ANTO COAG",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 384,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10983090,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOMPERIDONE",
        "predisposition": "DOMPERIDONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 139,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4600424,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FUSIDIC_ACID",
        "predisposition": "FUSIDIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 191,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6339775,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GINKGO_FOLIUM",
        "predisposition": "GINKGO FOLIUM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 21,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 602654,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYCOMYCIN_CD",
        "predisposition": "HYCOMYCIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 42,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1395653,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROGEN_PEROXIDE",
        "predisposition": "HYDROGEN PEROXIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 72,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2391866,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INDOMETACIN",
        "predisposition": "INDOMETACIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 44,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1265551,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IRINOTECAN",
        "predisposition": "IRINOTECAN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 15,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 427559,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LEMOCIN_CD",
        "predisposition": "LEMOCIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 138,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3968553,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MESALAZINE",
        "predisposition": "MESALAZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 113,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3756109,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METFORMIN",
        "predisposition": "METFORMIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 836,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 27625185,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METHOXY_POLYETHYLENE_GLYCOL.2DEPOETIN_BETA",
        "predisposition": "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 39,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1288276,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MULTIVITAMINS_.2B_MINERALS_CD",
        "predisposition": "MULTIVITAMINS + MINERALS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 191,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5467783,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NUSSIDEX.2FHISTADEX_CD",
        "predisposition": "NUSSIDEX/HISTADEX CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 238,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7870543,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OFLOXACIN",
        "predisposition": "OFLOXACIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 341,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 11328044,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OMEGA.2D3.2DTRIGLYCERIDES_CD",
        "predisposition": "OMEGA-3-TRIGLYCERIDES CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 258,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8505771,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXAZEPAM",
        "predisposition": "OXAZEPAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 416,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 11928785,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PANCRELIPASE",
        "predisposition": "PANCRELIPASE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 38,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1086944,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PANTOPRAZOLE",
        "predisposition": "PANTOPRAZOLE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 158,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 4519885,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PIROXICAM",
        "predisposition": "PIROXICAM",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 227,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7530537,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROTHIAZINE.2FPROMETHAZINE_EXPECTORANT_CD",
        "predisposition": "PROTHIAZINE/PROMETHAZINE EXPECTORANT CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 31,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 887463,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RAMIPRIL.2DHYDROCHLOROTHIAZIDE_CD",
        "predisposition": "RAMIPRIL-HYDROCHLOROTHIAZIDE CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 521,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 17339525,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RANITIDINE",
        "predisposition": "RANITIDINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 221,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 7352387,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.REPAGLINIDE",
        "predisposition": "REPAGLINIDE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 492,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 16288827,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RISPERIDONE",
        "predisposition": "RISPERIDONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 112,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3213003,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ROSUVASTATIN",
        "predisposition": "ROSUVASTATIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 709,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 23444715,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SILVER_DRESSING",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 24,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 688086,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SODIUM_BICARBONATE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 22,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 725702,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SODIUM_CHLORIDE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 277,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9138245,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.STREPSILS_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 373,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 12407037,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TAMSULOSIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 617,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 17749113,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TERBINAFINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 200,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5719663,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TOCOPHERYL_.28VITAMIN_E.29",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 419,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 13843868,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRIAMCINOLONE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 98,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2810537,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRIBEMIN.2FBTRIVIT_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 615,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 17537388,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRIHEXYPHENIDYL",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 132,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 4357960,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VALPROIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 867,
        "predisposition_and_risk": 253,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 8400146,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VALSARTAN.2DAMLODIPINE_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 379,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 10864383,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VILDAGLIPTIN.2DMETFORMIN_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 235,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 6737900,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VITAMIN_B_COMPLEX.2BVIT.2EC_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1.01,
        "risk_count": 811,
        "predisposition_and_risk": 17,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 487176,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AFLUMYCIN_CD",
        "predisposition": "AFLUMYCIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 208,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6932554,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALENDRONIC_ACID",
        "predisposition": "ALENDRONIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 763,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 25403864,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AMITRIPTYLINE",
        "predisposition": "AMITRIPTYLINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 291,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 8411896,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AMLODIPINE",
        "predisposition": "AMLODIPINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 774,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 22380811,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ASCORBIC_ACID.2DROSE_HIPS_CD",
        "predisposition": "ASCORBIC ACID-ROSE HIPS CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 62,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1786648,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ATORVASTATIN",
        "predisposition": "ATORVASTATIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 808,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 27022368,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BENAZEPRIL",
        "predisposition": "BENAZEPRIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 22,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 633686,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BISMUTH_SUBSALICYLATE",
        "predisposition": "BISMUTH SUBSALICYLATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 171,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 5694785,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BROMHEXINE",
        "predisposition": "BROMHEXINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 277,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 9256724,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CASTOR_OIL",
        "predisposition": "CASTOR OIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 23,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 765681,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CHLORAMPHENICOL",
        "predisposition": "CHLORAMPHENICOL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 460,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 15336867,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLOBETASONE",
        "predisposition": "CLOBETASONE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 27,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 780739,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLOMIPRAMINE",
        "predisposition": "CLOMIPRAMINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 46,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 1329400,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DESOREN.2FDEXOTIC_CD",
        "predisposition": "DESOREN/DEXOTIC CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 186,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5359179,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIABETES_LANCETS",
        "predisposition": "DIABETES LANCETS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 181,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 6034469,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENALAPRIL",
        "predisposition": "ENALAPRIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 802,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 23180870,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENALAPRIL",
        "predisposition": "ENALAPRIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 847,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 28309044,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EUCALYPTUS_OIL",
        "predisposition": "EUCALYPTUS OIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 23,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 767489,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EVOREL_CONTI_CD",
        "predisposition": "EVOREL CONTI CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 61,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2035249,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HTN.ARB",
        "predisposition": "HTN ARB",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 762,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 21991920,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HTN.BETA_BLOCKERS",
        "predisposition": "HTN BETA BLOCKERS",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 810,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 23377217,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDRALAZINE",
        "predisposition": "HYDRALAZINE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 74,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 2129411,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.JEVITY_LIQ.2E_CD",
        "predisposition": "JEVITY LIQ. CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 30,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 863992,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LANTHANUM_CARBONATE",
        "predisposition": "LANTHANUM CARBONATE",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 38,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1269586,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LOTEPREDNOL.2DTOBRAMYCI_CD",
        "predisposition": "LOTEPREDNOL-TOBRAMYCI CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 11,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 367603,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METFORMIN",
        "predisposition": "METFORMIN",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 782,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 22514920,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METFORMIN_AND_LINAGLIPTIN_CD",
        "predisposition": "METFORMIN AND LINAGLIPTIN CD",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 32,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1069498,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MYCOPHENOLIC_ACID",
        "predisposition": "MYCOPHENOLIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 100,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 3335562,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NET_DRESSING",
        "predisposition": "NET DRESSING",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 49,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1633995,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RAMIPRIL",
        "predisposition": "RAMIPRIL",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 748,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 24940243,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RISEDRONIC_ACID",
        "predisposition": "RISEDRONIC ACID",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 580,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 19336494,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SOFFODEX_CD",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 41,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 1366273,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TERAZOSIN",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 116,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 3354353,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIOCTIC_ACID",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 867,
        "predisposition_and_risk": 83,
        "risk_duration": 29002769,
        "predisposition_and_risk_duration": 2774415,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VENLAFAXINE",
        "predisposition": "NA",
        "risk": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "rr": 1,
        "risk_count": 811,
        "predisposition_and_risk": 192,
        "risk_duration": 23451865,
        "predisposition_and_risk_duration": 5527514,
        "type": "NA"
      }
    ],
    "figures": null,
    "messageType": "chronicDiseaseCohorts.report",
    "requestId": "a255e9c8-1d8f-41ad-b4de-916a0c0a1c52",
    "cohortId": "c_4e119a7b3d6488e8bfae3b8a184279f2"
  },
  "id": "a255e9c8-1d8f-41ad-b4de-916a0c0a1c52"
}